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Abstract 
The proton-dependent oligopeptide transporters (POTs) are ubiquitous in all 
kingdoms of life and the only peptide transport system in humans. Coupled to co-
transport of protons, they take up di- and tripeptides into the cell. Two human 
homologues are crucial for the nutrient (re)absorption and drug delivery. Human 
PepT1 (hPepT1, SLC15A1) is highly expressed in the small intestines, whereas 
hPepT2 (SLC15A2) is mainly found in the kidney. Indeed, antibiotics such as 
ceftibuten, medication against high blood pressure such as enalapril and antiviral 
drugs such as valacyclovir and valganciclovir are taken up by hPepT1 and hPepT2. 
Although these transporters have been studied biochemically in the past, structural 
information on any of the eukaryotic transporters is missing. High-resolution 
structures from bacterial homologues contributed to our understanding of ligand 
binding and selectivity but these transporters do not transport drugs. Exceptionally, a 
homologue from Escherichia coli, DtpA, shows a striking similarity to hPepT1 in 
terms of ligand selectivity and transports several different drug molecules. 
To characterize the ligand selectivity of DtpA further, I used a number of in vitro and 
in vivo methods: A ligand library consisting of di- and tripeptides and selected drugs 
was screened by differential scanning fluorimetry and microscale thermophoresis. 
Further, the screening was complemented by the established in vivo transport and 
competition assay. Both in vivo and in vitro data were in good agreement with the 
following conclusions: (1) DtpA has a significantly higher preference for tripeptides 
than dipeptides, and (2) prefers di- and tripeptides with hydrophobic and aromatic 
residues compared to charged residues. (3) Glycine containing ligands are less likely 
to bind and be transported by DtpA. From the drug library, valacyclovir and 
valganciclovir stood out with binding affinities similar to the ones the measured for 
di- and tripeptides. 
The structure of DtpA was determined using a nanobody as a crystallization 
chaperone in a ligand-free state at 3.3 Å and a valganciclovir-bound state at 2.7 Å. 
Valganciclovir, L-valyl ester of ganciclovir, is an antiviral prodrug used in the 
treatment of cytomegalovirus. The valine moiety increases the solubility and 
absorption rate of the compound. In fact, ganciclovir without the N-terminal valine 
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cannot be transported by hPepT1 or hPepT2. Because the N-terminal residue of a 
di-/tripeptide plays an important role for the ligand coordination in previous ligand-
bound bacterial structures, the valine moiety was suggested to be coordinated in the 
position of the N-terminal residue of a di-/tripeptide. However, in the DtpA-
valganciclovir structure, the guanine ring mimics the N-terminal residue and the 
valine moiety is coordinated in a previously uncharacterized pocket. This pocket is 
larger in DtpA compared to other studied POTs due to a structural difference in 
transmembrane helix 10 caused by an intrahelical loop. Transmembrane helix 11 is 
therefore shifted away from the ligand-binding site, which increases the pocket size 
and allows the transport of various drug molecules. 
In summary, I present the functional characterization of DtpA by combining in vivo 
and in vitro studies with a focus on ligand selectivity and bring new insights to this 
transporter. Furthermore, the DtpA-valganciclovir structure reveals an unexpected 
binding mode of the drug and an uncharacterized pocket within the ligand-binding 
site. Finally, we provide a homology model of hPepT1 laying the groundwork for 
further drug development. 
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Zusammenfassung 
Protonen-abhängige Oligopeptidtransporter (POT) kommen in nahezu allen 
Organismen vor und sind in Eukaryota das einzige Transportsystem für kurze Peptide. 
Die Aufnahme von Di- und Tripeptide in die Zelle ist an den Cotransport von 
Protonen gekoppelt. Die zwei humanen Transportproteine, hPepT1 und hPepT2, sind 
unentbehrlich für die Aufnahme von Eiweißen und Medikamenten. hPepT1 wird vor 
allem im Dünndarm und hPepT2 in den Nieren exprimiert. Das Antibiotikum 
Ceftibuten, das Bluthochdruck-Medikament Enalapril, die antiviralen Präparate 
Valacyclovir und Valganciclovir sowie weitere Medikamente werden von diesen 
Transportern in den Körper aufgenommen.  
Obwohl zahlreiche biochemische Studien mit hPepT1 und hPepT2 durchgeführt 
wurden, fehlen strukturelle Kenntnisse über diese pharmakologisch wichtigen 
Transportproteine. Die hochauflösende Strukturanalyse von bakteriellen Homologen 
bereicherten das Verständnis über die Ligandenbindung und –selektivität, aber diese 
Proteine transportieren keine Medikamente. Die Ausnahme bildet ein Homolog aus 
Escherichia coli, DtpA. DtpA nimmt wie hPepT1 Medikamente auf und zeigt 
darüberhinaus Ähnlichkeiten in der Ligandenselektivität.  
Um das Verständnis der Ligandenselektivität von DtpA zu vertiefen, habe ich in vitro 
und in vivo Methoden verwendet. Mittels Differential-Scanning-Fluorometrie (DSF) 
und Microscale Thermophoresis (MST) wurde die Ligandenbindung von DtpA 
anhand einer Bibliothek von Di- und Tripeptiden sowie Medikamenten untersucht. 
Diese Studie wurde mit einem etablierten in vivo Konkurrenztransportassay 
komplementiert. Die Ergebnisse waren übereinstimmend und sind in folgenden drei 
Punkten aufgelistet. (1) DtpA bevorzugt Tripeptide gegenüber Dipeptiden. (2) Di- 
und Tripeptide mit hydrophoben und aromatischen Seitenketten werden bevorzugt im 
Gegensatz zu Di- und Tripeptide mit geladenen Seitenketten. (3) Di- und Tripeptide, 
die Glycin beinhalten, werden nicht bevorzugt. Von den Medikamenten stachen nur 
Valacyclovir und Valganciclovir hervor.  
Die Struktur von DtpA wurde mit Hilfe eines Nanobodys als Kristallisationschaperon 
jeweils ohne einen Liganden und gebunden an Valganciclovir mit 3.3 Å und 2.7 Å 
Auflösung bestimmt. Valganciclovir ist der L-Valinylester von Ganciclovir, welches 
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in der Therapie von Cytomegalie eingesetzt wird. Der Valinrest erhöht die Löslichkeit 
und die Absorptionsrate von Valganciclovir. hPepT1 und hPepT2 transportieren nur 
Valganciclovir aber nicht Ganciclovir. Valacyclovir und Valganciclovir ähneln sich 
sehr stark in der chemischen Struktur. In vorherigen Strukturanalysen wurde eine 
wichtige Rolle der N-terminalen Aminosäure des Liganden zugeschrieben, 
darauffolgend wurde eine ähnliche Rolle für den N-terminalen Valinrestes für die 
Koordination von Valacyclovir in der Bindefalte von hPepT1 vorausgesagt. Entgegen 
der Voraussage nimmt der Guaninrest von Valganciclovir die Rolle der N-terminalen 
Aminosäure in der Bindefalte von DtpA ein, während der Valinrest in einer bisher 
unbekannten Bindetasche koordiniert wird. Diese Bindetasche in DtpA ist größer im 
Vergleich zu den anderen bekannten POT Strukturen. Dies wird durch eine 
Strukturänderung an den Transmembranhelices 10 und 11 hervorgerufen. 
Transmembranhelix 10 wird durch einen Loop unterbrochen, wodurch 
Transmembranhelix 11 von der Bindefalte weggeschoben wird. Dadurch entsteht eine 
größere Bindetasche, die Valganciclovir und höchstwahrscheinlich auch Tripeptide 
besser koordinieren kann.  
In dieser Arbeit wurde mittels in vivo und in vitro Methoden weitere Kenntnisse über 
die Ligandenbindung von DtpA gewonnen. Die Strukturanalyse von DtpA in 
Komplex mit Valganciclovir hat eine neue Bindetasche in den Fokus gebracht, die in 
der Bindung von Medikamenten und Tripeptide eine Rolle spielt. Zusätzlich wurde 
eine Homologiemodell von hPepT1 mit Valganciclovir auf Basis der neuen 
strukturellen Erkenntnisse des prototypischen DtpA berechnet, welches für die 
Medikamentenentwicklung verwendet werden kann. 
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Table 1: List of amino acids in three-letter- and one-letter-code 
Amino acid Three-letter-code One-letter-code 
Alanine Ala A 
Arginine Arg R 
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Aspartic acid Asp D 
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Glutamic acid Glu E 
Glutamine Gln Q 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 
Valine Val V 
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1. Introduction 
1.1. The membrane and membrane proteins  
Membranes play a crucial role in cell biology: they isolate the cellular compartments 
from the environment and they subdivide the cell into independent and specialized 
compartments. This is vital for keeping molecules within the cell and cellular 
organelles, and to maintain chemical gradients inside and outside of the cell or the 
organelles. Chemically, the membrane is a lipid bilayer with a hydrophobic core and a 
hydrophilic surface, where proteins are anchored or embedded. Thus, it is a dynamic 
and semi-permeable barrier to molecules, where many biochemical reactions occur. 
The membrane is a complex environment consisting of various types of lipids. It 
differs in lipid composition and lipid ratios across species (Hannich, Umebayashi, and 
Riezman 2011), between the different organelle membranes or even as an adaptation 
to the environmental growth conditions (O'Brien and Frerman 1980). Furthermore, 
the lipid composition in the two leaflets of the bilayer is asymmetric due to the high-
energy barrier for a lipid to swap to the opposite side. The lipids found in 
biomembranes can be grouped into three categories: (i) glycerophospholipids, (ii) 
sphingolipids and (iii) sterols (Figure 1). 
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Figure 1: Diversity of membrane lipids. 
(a) Glycerophospholipids (GPL) are illustrated with the glycerol backbone attached to 
two fatty acids and a head group. On the right possible head group substituents are 
listed (green box) as well as the chemical linkage between the glycerol backbone and 
the fatty acids (blue box). (b) Sphingolipids are presented with the sphingoid 
backbone linked to a N-acyl chain and a head group with the different sphingoid base 
types (pink box) and the head groups (green box). (c) Cholesterol molecule. (d) 
Common fatty acids in the lipid membrane. Figure modified from (Harayama and 
Riezman 2018). 
 
Glycerophospholipids are built on a glycerol-3-phosphate backbone, which is 
esterified to fatty acids at two positions and the phosphate is esterified with an alcohol 
head group, e.g. serine or inositol. In case of sphingolipids, instead of glycerol they 
are built on a sphingosine backbone linked to one fatty acid via a peptide bond and 
one alcohol esterified with the phosphate group. The fatty acids are typically 10 to 24 
carbon long acyl chains, which are called saturated if no double bond is present and 
unsaturated if at least one double bond is present within the carbon tail. Additionally, 
the phospholipids or sphingolipids can accommodate an oligosaccharide head-group. 
Finally, sterols are tetracyclic compounds formed of several isoprenyl groups. 
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Cholesterol is the most common sterol in the membrane of animals, ergosterol in 
fungi and stigmasterol and sitosterol in plants. Prokaryotes don’t have sterols in the 
membrane in the strict sense. Instead, hopanoids were identified in prokaryotic 
membranes, which are pentacyclic triterpenoids and functional sterol surrogates 
(Dufourc 2008; Sáenz et al. 2015). Functionally, lipids play additional roles in 
signaling, energy storage and as cofactors, precursors and pigments.  
Overall, the membrane is composed of several different lipids and their relative 
proportions strongly affect dynamics of the membrane. Although the transverse 
movement of the lipids (movement across the leaflets) is energetically unfavorable, 
they move laterally (within a leaflet) according to Brownian motion but due to their 
interaction with proteins, they are not randomly distributed across the bilayer. The 
membrane is crowded with proteins affecting the permeability. Only small neutral 
molecules can diffuse through a membrane but due to the crowdedness of the 
membrane by integral membrane proteins and sugars, the diffusion rates are very low, 
and even for these molecules transport systems are required (Agre 2004). 
 
 
Figure 2: Integral membrane proteins. 
There are three types of integral membrane proteins, α-helical proteins with either (a) 
a single helix or (b) multiple helices spanning through the membrane and (c) 
β-barrels, which consist of β-sheets. As an example, the structure of the human 
retinol-binding protein (PDB id: 1RBP) is illustrated.  
There are two types of membrane proteins, integral and peripheral. The integral 
membrane proteins are fully embedded in the membrane, with one or multiple 
α-helices spanning the hydrophobic core of the membrane (Figure 2). Typically, one 
transmembrane α−helix consists of 20-25 hydrophobic residues. According to the 
positive-inside rule positively charged residues (Lys, Arg, His) accumulate on the 
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cytoplasmic side of the protein and aromatic residues (Trp, Tyr and Phe) are often at 
the lipid water interface. There are also integral membrane proteins consisting of 
β-sheets, which form a membrane-spanning β-barrel (Figure 2). Every second residue 
of the β-sheets is a hydrophobic residue, orienting its side chain towards the “outside” 
of the barrel. The peripheral membrane proteins do not intrude through the 
hydrophobic core of the membrane. Their α-helices or loops interact with the 
hydrophilic lipid surface or other integral membrane proteins via electrostatic 
interactions or they are anchored covalently to lipids. Proteins on the extracellular 
peripheral site are often involved in the extracellular matrix, whereas on the 
intracellular side they have variable functions from interactions with the cytoskeletal 
proteins to soluble enzymes, which act on lipid molecules.  
Integral membrane proteins make up 20-30 % of most genomes (Krogh et al. 2001) 
and perform a variety of roles. For example, the electron transport chain consists of 
integral membrane proteins and is crucial for ATP synthesis, the energy unit of the 
cell. As in the case of the electron transport chain, the membrane proteins often move 
the substrate from one protein to the next like an assembly line with the membrane 
serving as the platform. The cells communicate with their environment and with each 
other via membrane receptors and adhesion proteins. There are enzymes, which act 
within the membrane, such as proteases. Transporters and channels carry the task of 
moving molecules across the membrane. The difference between transporters and 
channels is that channels have an open pore, which has a specific size for its substrate 
and remains open during the conducting phase to both sides of the membrane, 
whereas transporters open only to one side of the membrane at a given time point and 
need to go through conformation changes for the transport activity. In the next chapter 
the role of transporters will be discussed in more detail.  
1.2. Transporters 
The semi-permeable membrane allows a very limited number of molecules to pass 
through the membrane. Only small and neutral molecules fall into this category. The 
high number of proteins within the membrane further limits the simple diffusion. The 
membrane creates an electrochemical gradient, which is built by the different 
concentrations of molecules and of charges on both sides of the membrane. The 
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electrochemical gradient is an important factor for all transport activities across the 
membrane. The different types of transporter proteins are classified by the 
stoichiometry of solutes and/or the energy dependency of the transport mechanism. 
Depending on the stoichiometry, a transporter is called uniporter if only one molecule 
is transported during a transport cycle. If multiple molecules are transported, 
depending on the direction of the molecules relative to each other they are called 
symporters, for same direction, or antiporters, for opposite directions (Figure 3). 
 
 
Figure 3: Types of transport based on the stoichiometry 
Transporters, illustrated in green, are named (a) uniporters, if only one ligand is 
moved across the membrane. In case of multiple ligands, they are called (b) 
symporters, when the ligands are moved in the same direction or (c) antiporters, if in 
opposite directions. 
All processes of transport require energy. The electrochemical gradient is the driving 
force for the facilitated diffusion, where a molecule is transported from the high 
concentration side of the membrane to the low concentration side. Often a molecule 
needs to be transported against its concentration gradient. There are primary active 
transporters, which use the energy gained from ATP hydrolysis for the transport. 
ATP-binding cassette (ABC) transporters build the largest superfamily of primary 
active transporters. The secondary active transporters couple the transport of the 
molecule of interest to the co-transport of a proton, ion or solute along its 
electrochemical gradient. The major facilitator superfamily (MFS) is the largest and 
best studied superfamily of secondary active transporters. The ion channels transport 
ions along their concentration gradient. They are, as mentioned before, different from 
transporters in their mechanism and are open to both sides of the membrane. Another 
type of transport is via ionophore-mediated ion transport, in which a molecule binds 
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to the ions shielding its charge and moves it across the membrane to release it on the 
other side. Figure 4 shows the different types of transporters that are described above. 
In this thesis, the secondary active transporters and more specifically the major 
facilitator superfamily is in the focus.  
 
 
Figure 4: Types of transporters across the membrane 
Only small neutral molecules can trespass the membrane via simple diffusion without 
the need of a transporter. Other molecules need transporter proteins. Along their 
concentration gradient, they pass through the transporter protein via facilitated 
diffusion. Often molecules need to move against their concentration gradient, which 
requires energy. Primary active transporters use hydrolyses of ATP, whereas the 
secondary active transporters move an additional ion or solute along its concentration 
gradient to obtain the necessary energy for the transport. Other transport mechanisms 
are via ion channels and ionophore mediated ion transport. Figure modified from 
(Nelson, Lehninger, and M 2000) 
There are two commonly used classification systems for transporters. The Transport 
Classification Database (TCDB) is accepted by the International Union of 
Biochemistry and Molecular Biology. In this system, all transporters are categorized 
based on their transport mechanism, phylogenetic relations and substrate. They are 
given an identifier (ID), which is composed of five digits: V.W.X.Y.Z. The first digit, 
V is a number and classifies the transport mechanism, such as channel or primary 
active transporter. W is a letter and groups transporters to subclasses, followed by X, 
which is a number and defines the superfamily/family of transporters. The 
superfamily/family organization is not well defined in this classification system. Y, a 
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number, defines the subfamily/family of transporters and Z, a number, corresponding 
to a specific transporter. The other classification system is the solute carrier system 
(SLC) proposed by the HUGO Gene Nomenclature Committee (HGNC), which 
concentrates only on facilitators and secondary active transporters found in the human 
genome. The transporters are given an identifier as SLCnXm. n is a number and 
represents the protein family, X, a letter corresponding to the subfamily and m is a 
number given to a specific transporter. For example, the proton-dependent 
oligopeptide transporter family is 2.A.17 in the TCDB system and SLC15A according 
to the SLC classification. 
1.3. Major facilitator superfamily 
The major facilitator superfamily (MFS) of transporters is one of the oldest 
superfamilies of membrane proteins in evolution, being present in archea, prokaryotes 
and eukaryotes. It facilitates the transport of solutes through the membrane, either 
along their concentration gradient or against the concentration gradient coupled to co-
transport of other solutes or ions. MFS is responsible for the transport of a wide 
variety of molecules such as organic and inorganic ions, nucleotides, sugars, lipids 
and short peptides. Thus, they play an important role in the transport of nutrients into 
the cell and in the import and export of toxins and drugs. Therefore, they are highly 
relevant for drug delivery and pharmacokinetics in humans and drug resistance in 
bacteria.  
All transporters belonging to the MFS have a common structural fold consisting of 12 
transmembrane α-helices (TM) building the transporter core. The core is organized 
into two bundles, each 6 TMs long, called the N-terminal and C-terminal bundle. The 
arrangement of the two bundles is in 2-fold pseudo-symmetry with the symmetry axis 
going through the center of the molecule perpendicular to the membrane plane. Each 
bundle can be further dissected into two groups of 3 TMs each (Yan 2013). The first 
TM of each 3-TM group, namely TM1, -4, -7 and 10 are in the center of the protein 
and build the transport path. The second TM of each 3-TM group (TM2, -5, -8, -11) is 
on the periphery of the center and mediates the interactions between the N- and C-
terminal bundles. The third TM of each 3-TM group (TM3, -6, -9 and -12) is on the 
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outer shell of the transporter. There are additional soluble or transmembrane domains 
in some protein families.  
The transport mechanism of MFS transporters was postulated over 50 years ago 
before any structural information was available (Jardetzky 1966). The three described 
criteria were the following: (i) The transporter should have a cavity in the center of 
the protein where the molecule can fit in. (ii) The transporter should have two 
conformations, which are open to opposite sides of the membrane. (iii) The binding 
affinity of the molecule should vary to the different conformations of the transporter. 
With the structural information the first two points were confirmed and further 
extended with the occluded conformation. During a transport cycle, the transporter is 
open to one side of the membrane, where it binds the ligand. The “switch” of the 
conformation occurs by the coordinated movement of the two bundles like a rigid 
body motion. Through an occluded conformation, the transporter opens to the other 
side of the membrane. After the release of the ligand, the transporter switches back to 
the initial conformation. The transporter is at no time point open to both sides during 
the transport cycle. Several structures of MFS transporters have been determined from 
different families capturing different states of this process (Figure 5). Quistgaard et al. 
further refined the model by the observation of the crystal structures of partially-
occluded transporter structures, in which one TM end from each bundle comes closer 
as an intermediary step, called “clamping”, prior to the switching to the other 
conformation (Quistgaard et al. 2016). For a long time, only one conformation of the 
transport cycle was captured by structural analysis of a given protein (Figure 5) 
making it difficult to study and understand the mechanism of conformational changes. 
XylE and GLUT3 were the first cases with structures of the same protein captured in 
multiple conformations (Quistgaard et al. 2013; Deng et al. 2015).  
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Figure 5: Alternate access mechanism of MFS transporters 
The different conformations of MFS transporters are illustrated in the center starting 
in the outward open conformation, where the ligand, in red, can bind to the ligand-
binding site in the center of the molecule. Next, through an occluded state the 
transporter moves to the inward open state, where the release of the ligand takes 
place. Through a ligand-free occluded state, the starting state of outward open 
conformation is reached, and the cycle is complete. On the outer circle, selected MFS 
transporter structures are presented in blue (N-terminal bundle) and in grey (C-
terminal bundle). The protein family specific additional structural moieties are shown 
in yellow. Figure modified from (Yan 2015) 
The next point of this dissertation focuses on the description of a family of 
transporters classified within the MFS superfamily: the proton-dependent 
oligopeptide transporters. 
1.4. Proton-dependent oligopeptide transporters 
Prokaryotes have several transport systems to move short peptides across the 
membrane. Dipeptide permease (Dpp) and oligopeptide permease (Opp) systems 
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belong to the ATP-binding cassette (ABC) transporter superfamily, which are primary 
active transporters. Proton-dependent oligopeptide transporters (POTs) were initially 
named tripeptide permease (Tpp) until it was discovered that these transporters, 
unlike the Dpp and Opp families, belong to secondary active transporters and the 
MFS superfamily (Steiner, Naider, and Becker 1995). POTs are present in 
prokaryotes and eukaryotes, but no members have been found in archea. In 
eukaryotes, they are the sole protein family that can deliver short peptides into the 
cells and play a crucial role in nutrient uptake. With the inwardly directed proton 
electrochemical gradient, they transport di- and tripeptides and protons. Some POTs, 
including human PepT1 and PepT2 as well as DtpA from Escherichia coli, also 
transport peptidomimetic drugs into the cell (Brandsch, Knütter, and Bosse-Doenecke 
2008; Prabhala et al. 2017). 
POTs have the conserved MFS fold. The N- and C-terminal bundles, each consisting 
of 6 transmembrane helices (TMs), build the transporter core. The prokaryotic 
members have two additional TMs, namely HA and HB, which are inserted between 
the N- and C-terminal bundles as mentioned previously. The function of the HAHB 
domain remains unknown. Insertions between the N-terminal bundle and HAHB 
domain showed no change in functional assays but insertion between the HA and HB 
helices depleted the activity completely (Zhao et al. 2014). Some eukaryotic members 
including mammalian POTs have a soluble extracellular domain, which is connected 
to the TM9 and TM10 (Figure 6). The crystal structure of the extracellular domain 
(ECD) of PepT1 from Mus musculus and PepT2 from Rattus norvegicus was 
determined and the overall structure is two compactly packed immunoglobin-like 
folds (Beale et al. 2015) (Figure 6). A functional role in recruiting the intestinal 
protease trypsin to PepT1 was suggested based on the µM-affinity of the PepT1 ECD 
and trypsin but not chymotrypsin or pepsin but it is expected not to be the only 
function of this domain (Beale et al. 2015). 
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Figure 6: Model of hPepT1 and the crystal structure of PepT1 ECD 
The predicted transmembrane helices of hPepT1 are shown with the three signature 
motives of POTs highlighted in purple, pink and green. The predicted glycosylation 
sites are in blue. The structure of the extracellular domain of PepT1 from Mus 
musculus (Beale et al. 2015) is shown in a box on top left. 
There are three conserved sequence motives in POTs, namely the ExxERFxYY motif 
in TM1, PTR2_1 motif (G***AD***GK**TI***S **Y**G) in the loop between 
TM2 and TM3 and PTR2_2 motif (*FS*FY*AIN*GSL*) in TM5 (Daniel 2006) 
(Figure 6). The ExxERFxYY and PTR2_2 motives are involved in ligand binding 
however the PTR2_1 motif is distant from the ligand-binding site. It is a modified 
version of the MFS signature motif A and is expected to play a role in the 
conformational transition between the inward and outward open states (Jiang et al. 
2013; Zhao et al. 2014).  
There are to date eight published POT structures, all from bacterial background 
(Table 2) (Newstead et al. 2011; Solcan et al. 2012; Doki et al. 2013; Guettou et al. 
2013; Zhao et al. 2014; Boggavarapu et al. 2015; Parker et al. 2017; Minhas et al. 
2018; Quistgaard, Molledo, and Löw 2017). Few of them have been co-crystallized 
with di-/tripeptides or alafosfalin, a dipeptide mimetic, giving first insights to the 
ligand promiscuity and selectivity of these peptide transporters. Initially, POTs were 
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suggested to transport all combinations of amino acids as short peptides, but further 
studies show that there are differences between POT members in terms of their ligand 
selectivity. Single amino acids and tetrapeptides are not likely to be ligands and there 
is stereoselectivity for L-amino acids, although one D-amino acid in the ligand is 
tolerated in some cases (Daniel 2006). Some of the bacterial POTs have higher 
affinities towards dipeptides than tripeptides (Martinez Molledo et al. 2018), whereas 
other POTs have higher affinity towards tripeptides as shown in this thesis. The side 
chains at the N- and C-terminal position of a dipeptide has been shown to play an 
important role (Weitz et al. 2007; Guettou et al. 2014). Almost all ligand studies were 
performed as competition assays and there are scarcely any direct uptake studies, 
which should be considered in the interpretation of the ligand selectivity in the 
literature.  
 
Table 2: List of published POT structures 
POT/SLC5 Organism Year Co-crystallized with  
PepTSo Shewanella oneidensis 2010 Ligand-free 
PepTSt Streptococcus thermophilus 2012 Ligand-free, (AF, AAA)*, (AL, 
FA, AQ, DE)**, (FAL, FAQ, 
FAT)** 
GkPOT Geobacillus kaustophilus  2013 Ligand-free, Alafosfalin 
PepTSo2 Shewanella oneidensis 2013 Ligand-free, Alafosfalin, 
(AY(Br)A, AY(Br), AAA)*** 
DtpD Escherichia coli 2014 Ligand-free 
YePepT Yersinia enterocolitica  2015 Ligand-free 
PepTXc Xanthomonas campestris  2017 Ligand-free 
PepTSh Staphylococcus hominis  2018 CG-3M3SH 
*published in 2014, ** in 2018, *** published in 2017 
 
All POT structures with dipeptides and alafosfalin share a conserved binding mode. 
The ligand-binding site is shaped by multiple pockets, which accommodate the side 
chains of the ligand. Three such pockets have been investigated in further depth for 
PepTSt (Figure 7) (Martinez Molledo et al., 2018) and PepTSo2 (Guettou et al. 2014; 
Martinez Molledo et al. 2018). The pockets are rich in aromatic residues that can 
make hydrophilic, hydrophobic or aromatic interactions contributing to the 
promiscuity of the ligand-binding site. There are several residues involved in the 
peptide backbone binding such as two Asp (N156, N328 in PepTSt) and a Glu (E400 
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in PepTSt) coordinating the N-terminal end of a dipeptide and an Arg (R26 in PepTSt) 
and Tyr (Y30 in PepTSt) coordinating the peptide bond and the C-terminal carboxy 
group (Figure 7).  
 
Figure 7: PepTSt structure in complex with AlaLeu 
(a) Inward open PepTSt structure in surface model cut in half perpendicular to the 
membrane plane with the ligand AlaLeu in sticks model. (b) Zoom into the ligand 
binding site, the two aromatic residues F428 and W427 which are suggested to have a 
lid function are highlighted in orange. (c) Surface model of the ligand binding-site 
with pocket 1, which coordinates the N-terminal residue in green and pocket 2, which 
coordinates the C-terminal residue in yellow. (d) Residues coordinating the ligand 
backbone in sticks model and the distances ≥3.2 Å in black and 3.2-4 Å in yellow 
dashes. Figure from (Martinez Molledo et al. 2018). 
There are three published studies with tripeptides suggesting two different binding 
modes. In one of these studies, PepTSo2 was co-crystallized with AlaTyrAla including 
a bromide moiety at the tyrosine residue (Guettou et al. 2014). The binding mode was 
identical with a dipeptide, with the N-terminal two residue positions overlapping and 
the C-terminal residue of AlaTyrAla extending further into the ligand-binding site. In 
the other study, PepTSt was co-crystallized with AlaAlaAla showing a unique vertical 
binding mode as opposed to the horizontal binding mode of dipeptides (Lyons et al. 
2014). Nevertheless, further studies in our group with PepTSt challenged this model 
with the observations of a HEPES molecule in an identical position as the AlaAlaAla 
model during co-crystallization attempts with several ligands (Martinez Molledo et al. 
2018). PepTSt was co-crystallization with three further tripeptides (PheAlaAla, 
PheAlaGln, PheAlaThr) that agree with the horizontal placement of the tripeptides 
similar to the dipeptide binding mode (Martinez Molledo, Quistgaard, and Löw 
2018). Further functional and structural studies are required for the understanding of 
di-/tripeptide coordination in POTs and how POTs are promiscuous but retain a level 
of selectivity towards specific residues. There is also high interest in the investigation 
of drug binding in POTs for drug development. 
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1.5. DtpA 
Escherichia coli genome has four genes belonging to POT family, named ydgR, 
ybgH, yjdL and ydgR. Correspond proteins were named DtpA to DtpD, Dtp standing 
for di-/tripeptide permease. DtpA is one of the first and most studied POTs due to its 
similarity in substrate preference to hPepT1. ydgR gene (DtpA) was shown to be 
regulated by the EnvZ/OmpR two-component regulatory system, which is involved in 
the E. coli environment stress response (Goh, Siino, and Igo 2004). Unfortunately, no 
further studies followed the gene regulation or expression profile of DtpA to our 
knowledge. 
Few ligand uptake and competition assays were developed for DtpA to study its 
ligand selectivity. The most established method is the in vivo uptake of AK-AMCA 
(β-Ala-Lys-N-7-amino-4-methylcoumarin-2-acetic acid) (Weitz et al. 2007; Malle et 
al. 2011; Prabhala et al. 2014; Prabhala et al. 2017). AK-AMCA is a dipeptide 
mimetic coupled to a fluorescent molecule, which can be also taken up by hPepT1 
(Groneberg et al. 2001) and hPepT2 (Dieck et al. 1999). In this method, cells 
overexpressing DtpA are incubated with AK-AMCA and an additional substrate for 
competition assays followed by washing steps. The fluorescence is measured in whole 
cells, which corresponds to the uptake of AK-AMCA. In case of a good competitor, 
the AK-AMCA uptake drops to <5%, whereas for poor competitors the AK-AMCA 
uptake remains close to 100% normalized by the AK-AMCA uptake without a 
competitor. As examples AlaAla, D-AlaAla, GlyGln, LysAla, AlaAlaAla, cefadroxil 
and valacyclovir were shown to be good competitors, whereas AspGly, GlyLys, Ala-
D-Ala, ampicillin and levadopa are poor competitors (Weitz et al. 2007; Prabhala et 
al. 2014). A good competitor is likely to bind and be transported by DtpA, whereas a 
poor competitor is less likely to bind and be transported by DtpA. From these 
experiments following conclusions were drawn: (i) DtpA can transport several di- and 
tripeptides but not all possible combinations. (ii) Combinations of L-amino acids are 
preferred. A D-amino acid at the N-terminal position of a dipeptide is tolerated (at 
least in case of D-AlaAla) but a D-amino acid at the C-terminal position of a 
dipeptide (in case of Ala-D-Ala) is not a good competitor. (iii) A positively charged 
residue in the N-terminal position of a dipeptide but not in the C-terminal position is 
an efficient competitor of AK-AMCA. (iv) A negatively charged residue in the C-
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terminal position of a dipeptide but not in the N-terminal position is a good 
competitor of AK-AMCA, although the difference is not as severe as for positively 
charged residues. Nevertheless, one needs to be careful in the interpretation of the 
results because it is an indirect method based on competition rate and the direct 
uptake of a ligand cannot be measured in this method, except for AK-AMCA itself. 
Furthermore, most conclusions are based on testing very few combinations of 
residues in the N-terminal and C-terminal positions of a dipeptide. 
A new label-free cell based method was developed for DtpA using the pH sensitive 
dye pyranine (Prabhala et al. 2014). Based on the proton-dependent nature of the 
transport activity, the pH change causes a change in the fluorescence profile of 
pyranine. Pyranine was added in the buffer and is a cell impermeable chemical. With 
this method, LysAla, AlaAla and AlaAlaAla were shown to be causing a pH change, 
which is interpreted as ligand transport. For the dipeptide AlaLys and the amino acid 
Ala only no change in pH was detected. Additionally, DtpA (and DtpB) showed a pH 
change with tetraalanine, which was not detected with other methods. The authors 
suggested that tetraalanine is a low affinity ligand, which cannot compete with AK-
AMCA but nevertheless can be transported as observed from the pH change. It 
remains open, if single amino acids, tetrapeptides and several combinations of di-
/tripeptides might be ligands with very low affinity, which were not competing with 
AK-AMCA.  
With a liquid chromatography-mass spectroscopy method (LC-MS) , the direct uptake 
of six clinical drugs was tested with E. coli cells overexpressing DtpA as well as 
without overexpression (Prabhala et al. 2017). From the tested drugs oseltamivir, 
bestatin, valacyclovir and ampicillin are known to be taken up by hPepT1 but not 
levodopa (L-DOPA) (Brandsch, Knütter, and Bosse-Doenecke 2008). In the AK-
AMCA competition assay only bestatin and valacyclovir were good competitors but 
all five drugs were uptaken into cells via DtpA according to the LC-MS results and 
levodopa was not, which supports the similarity between DtpA and hPepT1 in ligand 
selectivity. Furthermore the direct uptake of radioactively labeled [3H]-Gly-Sar (used 
also in studies with hPepT1) and [3H]-Ala-Ala were measured with DtpA 
reconstituted in proteoliposomes (Harder et al. 2008; Bippes et al. 2013). From these 
methods, AK-AMCA is the most widely used method due to its relative simplicity, 
lack of necessity of facilities such as for mass spectroscopy or the need to work with 
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radioactive compounds. Nevertheless, none of these methods is perfect and there is 
further need for direct uptake methods and/or methods, which can be scaled up to 
measure a wider ligand library in parallel. 
In a random mutagenesis study, 35 single point mutations were tested with the AK-
AMCA uptake assay that led to a full or partial loss-of-function (LOF) (Malle et al. 
2011). The key findings were (i) Mutation of G78 and G86, two conserved glycines 
across POTs, led to LOF although they are not in proximity of the ligand-binding site 
according to the homology model. (ii) Mutation of M295 and F289 led to LOF 
additional to already characterized residues in proximity of the ligand-binding site. 
(iii) E56 and R305 single mutations led to LOF, whereas E56R/R305E rescues the 
LOF showing that E56 and R305 form a salt bridge, which is crucial for the function. 
Due to their position on a model based on the PepTSo structure (only available POT 
structure at the time of the study), they suggested a periplasmic salt bridge role. 
Despite the high interest in DtpA and several functional and mutational studies a 
high-resolution structure of DtpA has been elusive. The only structural information 
was the very low resolution negative-stain TEM (transmission electron microscopy) 
images, which confirmed the monomeric nature of the protein (Weitz et al. 2007). 
1.6. Valganciclovir and valacyclovir 
Herpesviruses (Herpesviridae) are DNA viruses, which are widely spread in humans. 
There are five species, which infect humans: herpes simplex virus (HSV) 1 and 2, 
varicella zoster virus, which causes chicken pox and shingles, Epstein-Barr virus and 
cytomegalovirus (CMV). HSV-1 and -2 cause blisters in the mouth, lips, nose or 
genitals and the World Health Organization (WHO) estimates that 67 % of people 
under age of 50 globally have HSV-1 infection (WHO fact sheet on HSV). Although 
cytomegalovirus infection is often symptomless in healthy people, it can be life 
threatening for people with immunodeficiency such as HIV patients, organ transplant 
recipients or newborn infants. A clinical study from USA in 2006 showed that 36 % 
of children between age 6 and 11 and 90% of all older than 80 years old were infected 
with CMV (Staras et al. 2006). Due to the latent phase of herpesviruses, a complete 
cure does not exist. Nevertheless, there are a few drugs that inhibit the viral 
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replication, such as ganciclovir (Fan-Havard, Nahata, and Brady 1989) and acyclovir 
(Schaeffer et al. 1978). Both are acyclic guanosine analogs that are 
monophosphorylated specifically by viral thymidine kinase to monophosphate 
derivates and further phosphorylated by host kinases to triphosphate analogues. The 
triphosphate analogues of guanosine inhibit the viral DNA polymerases, block the 
DNA chain elongation and thereby limit the virus replication. Acyclovir is highly 
selective for HSV-1, -2 and varicella zoster virus but is not very effective against 
CMV. Ganciclovir is effective against HSV-1, -2 and CMV, although due to the 
higher toxicity than acyclovir it is mainly used against CMV (De Clercq and Field 
2006). A common problem with both drugs was the poor water solubility and very 
low uptake rates via oral administration. 
 
 
Figure 8: Chemical structures of valganciclovir and valacyclovir. 
The guanine ring is highlighted with a green background and the N-terminal valine 
with an orange background. Both drugs have a chiral center at the Cα of L-valine and 
valganciclovir a second chiral center marked with an asterisk at the C2-position. 
L-valine esters of acyclovir and ganciclovir, namely valacyclovir and valganciclovir, 
were shown to improve the water solubility and uptake rate remarkably. The uptake 
rate of valacyclovir improved from 19 % to 60 %, and from 6 % to 60 % in case of 
valganciclovir (Jung and Dorr 1999). This increase was linked to hPepT1, which is 
highly expressed in the small intestines and transports valacyclovir and valganciclovir 
but not acyclovir or ganciclovir into the intestinal cells (Guo et al. 1999; Sugawara et 
al. 2000). Valacyclovir and valganciclovir is rapidly converted to acyclovir or 
ganciclovir and L-valine by cellular esterases. Valganciclovir has in addition to the 
chiral center at Cα of L-valine a chiral center at the C2 position (marked with an 
asterisk in Figure 8). The drug is a mixture of both diastereomers, both of which can 
be transported by hPepT1 and cleaved by the host esterases. The chiral center is lost 
after the cleavage. 
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1.7. Aims of the study 
The peptide transporter DtpA has been in the focus of the POT field due to its 
similarity to hPepT1 in ligand selectivity and its ability of drug transport. There is a 
high interest in hPepT1 because of its physiological role in nutrient uptake and 
pharmacokinetic role in the transport of a wide variety of peptidomimetic antibiotics, 
antiviral, anticancer and antiparkinson drugs/prodrugs in the small intestines. Due to 
several glycosylation sites and the low protein stability, hPepT1 is highly challenging 
to work with, but bacterial homologue DtpA from E. coli turned out to be an excellent 
model system. There have been a few POT structures published (Table 2), some of 
which were co-crystallized with di-/tripeptides or alafosfalin in the ligand binding 
site, but most of these transporters have been shown not to transport any drugs. 
To elucidate drug transport in the POT/SLC15 family of peptide transporters and 
characterize DtpA in further depth, the aims of this thesis were to: 
• Characterize the ligand preference of DtpA with a ligand library 
systematically using in vitro and in vivo assays 
• Determine the structure of DtpA with and without a drug 
• Investigate the difference between published POT structure with the aim to 
understand why DtpA (and hPepT1/2) can transport drugs, whereas other 
bacterial members cannot 
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2. Materials and Methods 
2.1. Materials 
2.1.1. Chemicals and consumables 
Table 3: Table of chemicals 
Chemicals Producer Catalog number 
1-(7Z-pentadecenoyl)-rac-glycerol (7.8 MAG)  Avanti Polar Lipids  #850531O  
1,4-Dithiothreit (DTT) Roth #6908.2 
Agarose for DNA electrophoresis  SERVA #11404.07 
Ampicillin sodium salt Roth #K029.3 
β-AK-AMCA Biotrend #BP0352 
Calcium chloride Roth #5239.2 
cOmplete, EDTA-free protease inhibitor cocktail  Roche #5056489001 
D(+)-Glucose Roth #X997.2 
D(+)-Sucrose Roth #4621.1 
di-Sodium hydrogen phosphate heptahydrate  Roth #X987.2 
Dimethyl sulfoxide (DMSO) Sigma Aldrich #D2650  
DNAse I AppliChem #A3778 
Ethanol Roth #9065.3 
Ethidium bromide solution, 0.025 % (w/v) Roth #HP47.1 
Glucose  Roth  #X997  
Glycerol Roth #3783.1 
Glycine, Pufferan Roth #3908.2 
H-p-Bz-Phe-OH (pBpF) Bachem #4017646 
HEPES, Pufferan >99.5 %  Roth #9105.3 
Imidazole Roth #X998.4 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) Roth #2316.5 
Kanamycin sulphate Roth #T832.4 
LB Agar (Lennox) Roth #X965.2 
LB Broth Low Salt Granulated Melford #GL1703 
Magnesium chloride hexahydrate Roth #2189.1 
n-Dodecyl-β-D-Maltopyranoside (DDM), anagrade Anatrace #D322LA 
n-Dodecyl-β-D-Maltopyranoside (DDM), sol-grade Anatrace #D310S 
Nickel(II) chloride hexahydrate ≥ 98 %, p.a  Roth  #4489 
Polyethylen glycol 400 (PEG 400)  Fluka #91893 
Polyethylen glycol 600 (PEG 600)  Fluka #87333 
Sekusept Plus Ecolab  #104372E 
Sodium chloride, >99,5%, p.a., ACS, ISO  Roth  #3957 
Sodium dihydrogen phosphate monohydrate Roth #K300.2 
Sodium hydroxide ≥ 99 Roth  #9356  
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Sodium phosphate dibasic dodehydrate  Sigma-Aldrich  #71649 
Super signal West pico luminol/enhancer solution Thermo Scientific #1856136 
Super signal West pico luminol/enhancer solution Thermo Scientific #1856135 
TBE Buffer 10x, Rotiphorese Roth #3061.2 
TBST Sigma Aldrich #91414 
Terrific Broth (TB, modified), granular Melford  #GT1702 
Tris Acetate-EDTA (TAE) buffer 10X  Sigma-Aldrich  #T8280 
Tris-(hydroxymethyl)-aminomethane (TRIS) Roth #5429.3 
 
Table 4: Ligand library 
Category Ligand One letter code Producer Catalog number 
Dipeptide Ala-Ala AA Sigma #A502 
Dipeptide Ala-Asp AD Sigma #A9627 
Dipeptide Ala-Gln AQ Sigma #G8541 
Dipeptide Ala-Glu AE Bachem #4002318 
Dipeptide Ala-Leu AL Sigma #A1878 
Dipeptide Ala-Lys AK Bachem #G-1290 
Dipeptide Ala-Phe AF Sigma #A3128 
Dipeptide Asp-Glu DE Sigma #A1916 
Dipeptide Glu-Glu EE Sigma #G3640 
Dipeptide Gly-His GH Sigma #G1627 
Dipeptide Gly-Ser GS Sigma #G-3127 
Dipeptide His-Ser HS Sigma #H3129 
Dipeptide Leu-Ala LA Bachem #G-2460 
Dipeptide Leu-Leu LL Bachem #M-1535 
Dipeptide Lys-Ala KA Bachem #G-2630 
Dipeptide Met-Ser MS Sigma #M9380 
Dipeptide Phe-Ala FA Bachem #G-2850 
Dipeptide Thr-Gln TQ Sigma #T3275 
Tripeptide Ala-Ala-Ala AAA Bachem #H-1445 
Tripeptide Ala-Ala-Tyr AAY Bachem #G-1445 
Tripeptide Ala-Leu-Ala ALA Bachem #H-5975 
Tripeptide Ala-Phe-Ala AFA Bachem #H-5420 
Tripeptide Ala-Pro-Ala APA Bachem #H-1595 
Tripeptide Gly-Gly-His GGH Sigma #G4541 
Tripeptide Leu-Gly-Gly LGG Sigma #L9750 
Tripeptide Leu-Leu-Ala LLA Bachem #H-3905 
Tripeptide Met-Ala-Ser MAS Sigma #M1004 
Tripeptide Phe-Ala-Ala FAA GL Biochem 
Drug 5-Aminolevulinic acid Sigma #A3785 
Drug Midodrine 
 
Sigma #M8277 
Drug Palmidronate Sigma #P2371 
Drug Penicillin G sodium salt Sigma #13752 
Drug Valacyclovir Sigma #PHR1601 
Drug Valganciclovir Fluka #PHR 1626 
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Table 5: Enzymes and commercial kits 
Enzymes and commercial kits Producer Catalog number 
DNase I recombinant Roche #4536282001 
DpnI restriction enzyme New England BioLabs #R0176S 
Lysozyme Roth #8259.2 
Mix & Go! E. coli Transformation Kit Zymo Research #T3001 
Monolith His-Tag Labeling Kit RED-tris-NTA Nanotemper #MO-L008 
Phusion High-Fidelity DNA Polymerase New England BioLabs #M0530S 
QIAquick Gel Extraction Kit Qiagen  #28706 
QIAquick Miniprep Kit Qiagen  #27104 
QIAquick PCR Purification Kit  Qiagen  #28106 
T4 DNA Ligase New England BioLabs #M0202S 
T4 DNA Polymerase New England BioLabs #M0203S 
T4 Polynucleotide Kinase New England BioLabs #M0201S 
Taq DNA Polymerase New England BioLabs #M0267S 
 
Table 6: Table of consumables 
Consumables Producer Catalog number 
CaptureSelect beads for EPEA-tag  ThermoFisher Scientific #194288010 
Monolith NT.115 Capillaries  Nanotemper #MO-K022 
Monolith NT.LabelFree Standard Capillaries  Nanotemper #MO-Z022 
Ni-NTA Agarose Invitrogen #R901-15 
NuPAGE® LDS Sample Buffer (4X) ThermoFisher Scientific #NP008 
NuPAGE® Novex® 4-12% gels  ThermoFisher Scientific #NP0322 
Prometheus NT.48 Standard Capillaries  Nanotemper #PR-C002 
Roti®-Mark 10-150 Protein-Marker   Roth #T850 
Spin-X® UF 100 kDa concentrator  Corning #431491 
Spin-X® UF 5 kDa concentrator  Corning #431487 
Spin-X® UF 50 kDa concentrator  Corning #431490 
 
Table 7: Commercial crystallization screens 
Crystallization screens 
Method of 
crystallization Supplier Catalog no. 
MemGold_HT-96 vapor diffusion Molecular Dimensions MD1-41 
MemGold2_HT-96 vapor diffusion Molecular Dimensions MD1-64 
Wizard Cubic LCP Screen LCP Rigaku Reagents, Inc 1008650 
MemMeso HT-96 LCP Molecular Dimensions MD1-87 
Additive_screen additive screen Hampton Research HR2-428 
MemAdvantage additive screen Molecular Dimensions MD1-70 
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2.1.2. Devices 
Table 8: Table of devices 
Device Producer 
AKTA Pure with fraction collector F9C GE Healthcare 
Analytical gel filtration system Agilent Technologies 
Centrifuge Avanti JXN-26 Beckman-Coulter  
Electrophoresis chamber for agarose gels  NeoLab  
Electrophoresis chamber for SDS-PAGE gels Invitrogen 
EmulsiFlex-C3 cell homogenizer  Avestin 
Gel imaging and documentation system  Bio-Rad  
HiLoad 16/600 Superdex200 (gel filtration column) GE Healthcare 
HiLoad 16/600 Superdex75 (gel filtration column) GE Healthcare 
JLA 8.1000 rotor  Beckman-Coulter  
Monolith NT.115 microscale thermophoresis Nanotemper 
Monolith NT.LabelFree microscale thermophoresis Nanotemper 
Mosquito-LCP TTP Labtech  
New BrunswickTM Innova® 42 small shaking incubator  Eppendorf  
New BrunswickTM Innova® 44 shaking incubator  Eppendorf  
PCR cycler  Eppendorf  
Power supply  Consort  
Prometheus NT.48 nano differential scanning fluorimetry Nanotemper 
Rock Imager Formulatrix  
Scorpion dispenser Art Robbins Instruments  
Superdex200 Increase 10/300 GL (gel filtration column) GE Healthcare 
Thermoblock Eppendorf  
Ti 45 rotor Beckman-Coulter  
Ultracentrifuge Optima XE-90 Beckman-Coulter  
Ultracentrifuge tubes (polycarbonate, 70 ml tubes) Beckman-Coulter  
2.2. Methods 
2.2.1. Molecular Biology methods 
2.2.1.1. Transformation 
50 µL competent cells were mixed with 2 µL of plasmid and incubated 15 min on ice. 
The sample was introduced to 42 °C for 45 s followed by addition of 600 µL of LB 
buffer. The cells were incubated for another 15 min on ice. Cells with ampicillin-
resistant plasmids were directly plated out on LB-Agar plates supplemented with 
0.1 mg/ml ampicillin. For kanamycin-resistant plasmids, one-hour incubation at 37 °C 
 37 
shaking at 220 rpm was included before plating on LB-Agar plates supplemented with 
0.1 mg/ml kanamycin. Colonies grew on the plates overnight at 37 °C. 
2.2.1.2. Colony PCR 
Colony PCR reaction was performed with the components listed in Table 9 mixed 
with a colony that grew on the agar plate with the settings as in Table 10. This method 
was used at the final stages of a cloning experiment to test the size of a band in gel 
electrophoresis as described in Methods section 2.2.1.3. Colonies with the right size 
were sent for sequencing to confirm the sequence of the construct as further explained 
in Methods section 2.2.1.5. 
Table 9: Colony PCR components 
 
Volume for 1 reaction [µL] 
5 x Thermo buffer 2.5 
10 mM dNTPs 0.5 
10 µM forward primer 0.5 
10 µM reverse primer 0.5 
Taq polymerase 0.125 
fill up with water to  25 
 
Table 10: Settings of the colony PCR 
Step Temperature [°C] Time 
 1 95 1 min 
 2 95 30 s 
 3 55 30 s 
 4 68 1 min Go to step 2 for 30 cycles 
5 68 5 min 
 6 4 hold 
  
2.2.1.3. Agarose gel preparation 
1 % Agarose gel was prepared with TBE (TRIS/Borate/EDTA) buffer and a drop of 
EtBr (ethidium bromide). After polymerization and loading with the DNA samples, 
the gel was placed in the electrophoresis chamber, filled with 1x TBE buffer and 
110 V was applied for 45 min. The gel was imaged with ChemiDoc MP (Bio-Rad). 
2.2.1.4. Plasmid preparation 
Plasmid preparation was performed with the QIAprep Spin Miniprep Kit (Qiagen) 
according to the protocol of the manufacturer. 
 38 
2.2.1.5. Sequencing 
Samples were sent to Eurofins (Hamburg, Germany) for sequencing and the T7 
forward and T7 reverse primers were used for DtpA wild-type and mutants. For the 
nanobodies the MP57 and GIII primers (Pardon et al. 2014) were used to sequence the 
constructs from the N-terminal or C-terminal end. 
Table 11: Primers for sequencing 
 
Primer sequence 
T7 forward 5’-TAATACGACTCACTATAGGG-3’ 
T7 reverse 5’-CTAGTTATTGCTCAGCGGT-3’ 
MP57 (forward) 5’-TTATGCTTCCGGCTC GTATG-3’ 
GIII (reverse) 5’-CCACAGACAGCCCTCATAG-3’ 
 
2.2.1.6. Blunt-end PCR for site-directed mutagenesis 
To introduce site-directed point mutations in DtpA, blunt-end PCR method was used. 
A set of primers was designed for each mutant, which had the 5’-ends on the aimed 
site of the point mutation. In one of the primers the modified nucleotides for the 
mutation were included (highlighted in red in Table 12), the other primer was 
adjacent to that site. The primers were designed in reverse direction to span the whole 
vector. The components in the Table 13 were mixed on ice and a polymerase chain 
reaction (PCR) was performed with the settings as in Table 14. 
 
Table 12: Primers for site-directed mutagenesis of DtpA 
Mutant Direction Primer sequence 
Y38A forward 5'-GCATAACCAAAACGTTCC-3' 
 
reverse 5'-GGGCCTACAAGGAATTATG-3' 
Y71A forward 5'-GCAACCAGGGCACTAAAG-3' 
 
reverse 5'-GGGTCTGGTCGCTATCG-3' 
K130A forward 5'-GCAAACAGGCCGTTACC-3' 
 
reverse 5'-GGCTAACCCGTCTTCTCTG-3' 
N160A forward 5'-GACGGACATGTAGTACATGGTGAATG-3' 
 
reverse 5'-GCCATCGGCTCTTTCTTCTCTA-3' 
I399A forward 5'-CATCAGTTCCCCGATG-3' 
 
reverse 5'-GCGTCTGGTCTGGGT-3' 
The changed nucleotides are highlighted in red for introducing the aimed mutation. 
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Table 13: Blunt-end PCR components 
 
Volume for 1 reaction [µL] 
5 x Phusion buffer 5  
10 mM dNTPs 0.5  
10 uM fwr primer 1.25  
10 uM rev primer 1.25 
Phusion polymerase 0.25  
DNA template 1  
fill up with water to  25  
 
Table 14: Settings of the blunt-end PCR 
Step Temperature [°C] Time 
 1 98 1 min 
 2 98 30 s 
 3 60 30 s 
 4 72 5 min go to step 2 for 40 cycles 
5 98 10 min 
 6 4 hold 
  
The PCR product was inspected via gel electrophoresis (Methods section 2.2.1.3), 
mixed with 1 µL DpnI and incubated for one hour at 37 °C followed by purification 
with the QIAquick PCR purification kit according to manufacturer’s protocol. Then, 
30 µL of PCR product was mixed with 4 µL 10 x Polynucleotide ligase buffer, 1 µL 
T4 Polynucleotide kinase and filled up to 40 µL with water. After two hours of 
incubation at 37 °C, it was again purified with a QIAquick PCR purification kit. Next, 
30 µL phosphorylated PCR product was mixed with 4 µL of 10x Ligation buffer, 
2 µL of T4 DNA ligase and filled up to 40 µL. The ligated vector was transformed 
into E. coli DH5α cells as described in Methods section 2.2.1.1. Several colonies for 
each construct were used for colony PCR method as described in Methods section 
2.2.1.2 to check for the correct length of the vector and sent for sequencing to confirm 
the sequence (Methods section 2.2.1.5). 
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2.2.2. Protein expression and purification methods 
2.2.2.1. DtpA expression and purification 
2.2.2.1.1. Required buffers and stocks for expression 
• Plasmid of DtpA in pTH27 vector  
• E. coli C41 (DE3) competent cells  
• Lysogeny broth (LB) medium 
• Terrific broth (TB) medium 
• Ampicillin stock solution, 100 mg/ml 
• Isopropyl β-D-1-thiogalactopyranoside (IPTG) stock solution, 1 M 
2.2.2.1.2. Required buffers and stocks for purification  
• Lysis buffer: 20 mM NaP pH 7.5, 300 mM NaCl, 5 % glycerol, 15 mM 
imidazole 
• cOmplete, Mini, EDTA-free Protease Inhibitor cocktail tablets 
• Lysozyme stock solution, 100 mg/ ml 
• TCEP stock solution, 0.5 M 
• DTT stock solution, 0.5 M 
• DNAse stock solution, 2000 U/ ml 
• DDM, sol-grade powder 
• DDM stock solution, 3 %   
• Wash buffer 1: 20 mM NaP pH 7.5, 300 mM NaCl, 5 % glycerol, 15 mM 
imidazole, 0.03% DDM, 0.5 mM TCEP 
• Wash buffer 2: 20 mM NaP pH 7.5, 300 mM NaCl, 5 % glycerol, 40 mM 
imidazole, 0.03% DDM, 0.5 mM TCEP 
• Elution buffer: 20 mM NaP pH 7.5, 150 mM NaCl, 5 % glycerol, 300 mM 
imidazole, 0.03% DDM, 0.5 mM TCEP 
• Gel filtration buffer: 20 mM HEPES, pH 7.5, 150 mM NaCl, 5 % glycerol, 
0.5 mM DTT, 0.03% DDM 
• TEV protease stock solution, 1 mg/ml, stored at -80 °C 
 
2.2.2.1.3. Expression and purification protocol 
DtpA, wild type (WT) and mutants, were expressed and purified as previously 
described (Flayhan et al. 2018). The full-length dtpA (Uniprot ID: P77304) gene was 
amplified from the E. coli genome and cloned into the pTH27 vector (Woestenenk et 
al. 2004). The construct has an N- and C-terminal His-tag and a TEV cleavage site 
after the N-terminal tag. The C-terminal tag cannot be cleaved. 50 µL of competent E. 
coli C41 (DE3) cells were transformed with 2 µL of DtpA plasmid (Methods section 
2.2.1.1) and plated on a LB agar plate supplemented with 0.1 mg/ml ampicillin. 5 mL 
LB medium supplemented with 0.1 mg/ml ampicillin was inoculated with a colony 
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from the plate and incubated at 37 °C shaking at 220 rpm. After five to seven hours, 
the culture was extended to 50 mL and incubated at 37 °C shaking at 220 rpm 
overnight. 1 L TB supplemented with 0.1 mg/ml ampicillin was inoculated with the 
overnight culture for a starting OD600nm in 2 L baffled bottles and incubated at 37 °C 
shaking at 220 rpm until the OD600nm reached 0.7. The bottles were moved to room 
temperature for 30 min and the shakers cooled to 18 °C. The DtpA expression was 
induced with 0.2 mM IPTG and the incubation continued at 18 °C shaking at 220 rpm 
overnight. The cells were harvested by centrifugation at 10,000 xg for 12 min and the 
pellet stored at -20 °C until purification. 
For purification, the cell pellet was resuspended in lysis buffer with 5 units/ml DNase, 
1 tablet of proteinase inhibitor/100 mL, 1 mg/ml lysozyme and 0.5 mM TCEP. 3 to 5 
mL of lysis buffer was used per 1 g of cell pellet. Cell lysis was performed with an 
emulsifier (EmulsiFlex-C3, Avestin) in three passages at 10,000-15,000 psi pressure. 
All following steps were performed at 4 °C. The lysate was centrifuged 12 min at 
10,000 xg to remove the unlysed cells. The supernatant (SN) was ultracentrifuged 
50 min at 35,000 rpm using the rotor Ti45 (95,000 xg) (Optima XE-90, Beckman 
Coulter). The pellet containing the membrane fraction was solubilized with a potter 
resuspending the pellet in equal volume of lysis buffer with 1 tablet of proteinase 
inhibitor/100 mL and 0.5 mM TCEP. The suspension was incubated with 1 % (m/v) 
dodecylmaltoside (DDM) (Anatrace, sol-grade) mixing for 1 h to solubilize the 
membrane proteins. Then, it was ultracentrifuged 50 min at 30,000 rpm using the 
same rotor. The SN was applied to Ni-IMAC beads (ThermoFischer), which were 
equilibrated in wash buffer 1. For 1 L cell culture, 1 gravity column filled with 2 mL 
Ni-IMAC beads were used. SN with beads was incubated for 45 min on a rotating 
wheel and then was applied on a gravity column. The beads were washed twice with 
12 mL wash buffer 1 per column, followed by washing twice with 12 mL wash buffer 
2 per column. DtpA was eluted by adding 8 mL elution buffer for each column and 
combining the elution fractions in one tube. 0.5 mL TEV protease (1mg/ml) was 
added to the elution and the cleavage was performed in a dialysis bag in 0.5 L gel 
filtration buffer under light stirring overnight. DtpA was concentrated using a 50 kDa-
concentrator (Corning Spin-X UF concentrators) by 12 min centrifugation steps to 5 
mL and loaded on a HiLoad 16/600 Superdex 200 pg column (GE Healthcare) in 
AKTA system, which was previously equilibrated with the gel filtration buffer. The 
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fractions corresponding to the DtpA peak were collected and concentrated to 
11 mg/ml using a 50 kDa cut-off concentrator. Part of the protein sample was used 
fresh for crystallization and the rest was flash-frozen and stored at -80 °C until further 
use. 
2.2.2.2. Nanobody expression and purification 
2.2.2.2.1. Required buffers and stocks for expression 
• Plasmid of nanobody in pMESy4 vector 
• E. coli WK6 competent cells 
• Lysogeny broth (LB) medium 
• Terrific broth (TB) medium 
• Ampicillin, 100 mg/ml stock solution 
• Isopropyl β-D-1-thiogalactopyranoside (IPTG), 1 M stock 
• Glucose stock solution (filtered), 20 %   
• MgCl2 stock solution (filtered), 2 M 
 
2.2.2.2.2. Required buffers and stocks for purification 
• TES buffer: 0.2 M TRIS, pH 8, 0.5 mM EDTA, 0.5 M sucrose 
• TES/4 buffer: 4-times diluted TES buffer with water 
• cOmplete, Mini, EDTA-free Protease Inhibitor cocktail tablets 
• Wash buffer: 20 mM NaP, pH 7.5, 20 mM NaCl 
• Elution buffer: 20 mM HEPES, pH 7.5, 1.5 M MgCl2 
• Gel filtration buffer: 20 mM HEPES, pH 7.5, 150 mM NaCl, 5 % glycerol 
 
2.2.2.2.3. Expression and purification protocol 
Nanobodies were generated by Jan Steyaert and Els Pardon at the Vrije University in 
Brussels with the provided DtpA sample, which was purified as described in Methods 
section 2.2.2.1. I have received the nanobodies in pMESy4 vector and the construct 
included a periplasmic signaling peptide and a C-terminal EPEA-tag (GluProGluAla-
tag). The expression and purification of nanobodies was performed as described in 
Pardon et al. (Pardon et al. 2014). 50 µL of E. coli WK6 cells were transformed with 
2 µL of nanobody plasmid and plated on a LB-Agar plate supplemented with 
0.1 mg/ml ampicillin. 5 mL LB medium supplemented with 0.1 mg/ml ampicillin was 
inoculated with a colony from the plate and incubated at 37 °C shaking at 220 rpm. 
After five to seven hours, the culture was expanded to 50 mL and incubated at 37 °C 
shaking at 220 rpm overnight. 500 mL TB supplemented with 0.1 mg/ml ampicillin, 
 43 
0.1 % glucose and 1 mM MgCl2 was inoculated with the overnight culture for a 
starting OD600nm of 0.05 in a 2 L baffled bottle and was incubated at 37 °C shaking at 
220 rpm until the OD600nm reached 0.7. The protein expression was induced with 
1 mM IPTG and the incubation continued at 28 °C shaking at 220 rpm overnight. The 
cells were harvested by centrifugation at 10,000 xg for 12 min and the pellet stored at 
-20 °C until purification. 
The cells were resuspended by stirring the cell pellet with TES buffer supplemented 
with 1 proteinase inhibitor pellet for 1 h at 4 °C. As a rule of thumb, 3 to 5 mL TES 
buffer was used per 1 g cell pellet. As the nanobodies were expressed into the 
periplasmic space, only the outer cell membrane was disrupted by osmotic shock 
adding two times the volume as in the previous step of TES/4 buffer and stirred for 
further 45 min. The intact cells were removed by centrifugation for 20 min at 
10,000 xg. The SN containing the nanobodies was ultracentrifuged 30 min at 
40,000 xg. The SN thereof was applied to a column packed with 10 mL CaptureSelect 
beads (ThermoFisher Scientific) via sample pump, which were pre-equilibrated with 
wash buffer in AKTA system using a flow rate of 2.5 ml/min. The column was 
washed with 5 column volumes (CV) of wash buffer and 5 % elution buffer at a flow 
rate of 4 ml/min, which was kept constant for all further steps. The nanobody was 
eluted with 8 CV elution buffer via a gradient from 5 to 100 % elution buffer. The 
fractions corresponding to the nanobody peak were collected and concentrated using a 
5 kDa cut-off to 5 mL, which was injected to HiLoad 16/600 Superdex 75 pg column 
on AKTA system that was previously equilibrated with gel filtration buffer. The 
fractions of nanobody were collected and concentrated with a 5 kDa cut-off to 
13 mg/ml. Finally, they were aliquoted in 50 or 100 µL batches, flash-frozen and 
stored at -80 °C until further use. 
2.2.2.3. DtpA purification coupled to N00 
2.2.2.3.1. Required buffers and stocks for purification 
• Gel filtration buffer: 20 mM HEPES, pH 7.5, 150 mM NaCl, 5 % glycerol, 
0.5 mM DTT, 0.03 % DDM 
• Elution buffer: gel filtration buffer with 2 M MgCl2  
• TEV protease stock solution, 1 mg/ml, stored at -80 °C 
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2.2.2.3.2. Purification protocol 
For the purification of DtpA coupled to N00 the same buffers and procedure were 
used as described in Methods section 2.2.2.1 for DtpA and 2.2.2.2 for N00 except the 
modified steps as written below. 
The DtpA purification was performed until the affinity purification step. Instead of 
the IMAC purification, the DtpA sample was applied to CaptureSelect beads, which 
were pre-loaded with N00 and washed with gel filtration buffer for 2 CV. After the 
application of DtpA, the column was washed with gel filtration buffer for 5 CV and 
eluted in 2 CV with 75 % elution buffer. The fractions corresponding to the DtpA-
N00 complex peak were collected. 0.5 mL of TEV protease (1 mg/ml) was added to 
the collected fractions and dialysed overnight in gel filtration buffer. Afterwards, the 
sample was concentrated using a 100 kDa cut-off to 5 mL and injected to HiLoad 
16/600 Superdex 200 pg column on AKTA system that was previously equilibrated 
with the gel filtration buffer. The fractions of the DtpA-N00 complex were collected 
and concentrated to 10 mg/ml using a 100 kDa concentrator. Part of the protein 
sample was used directly for crystallization and the rest was flash-frozen and stored at 
-80 °C until further use. 
2.2.3.  Biophysical techniques 
2.2.3.1. Analytical gel filtration assay 
Complex formation of DtpA and the nanobodies were studied with analytical gel 
filtration assay, which was performed with a Superdex 200 5/150 GL home-packed 
column (GE Healthcare) connected to the 1260 Infinity liquid chromatography system 
(Agilent technologies) at 10 °C. The concentration of the DtpA was 0.2 mg/ml and 
the nanobodies were in 1:1.2 molar ratio to DtpA. Runs of individual proteins as well 
as DtpA-nanobody mixtures were performed in a row. First, DtpA and one nanobody 
were mixed and measured and then DtpA was mixed with combinations of two 
nanobodies. The column was equilibrated with two column volumes of gel filtration 
buffer followed by the injection of 20 µL of sample. UV absorption and the 
fluorescence (excitation at 280 nm and emission at 350 nm) were recorded. All 
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samples were run in duplicates and the data analysis was performed in GraphPad 
Prism 5.0. 
2.2.3.2. Western blot analysis of DtpA-nanobody binding mode 
To investigate if nanobodies generated against DtpA are conformational or linear 
binders, a western blot method was developed.  The principle of this approach is 
shown in the Figure 9. 0.3 and 0.03 µg DtpA, 0.3 and 0.03 µg DtpC (another POT 
member from E. coli) as negative control and 15 µg nanobody 00 (N00) as positive 
control were loaded on a 4-12 % Bis-TRIS gel (ThermoFisher) and electrophoresis 
under reducing conditions was performed. The protein was transferred to a 
polyvinylidene difluoride (PVDF) membrane. 1% bovine serum albumin in TBS-T 
(TRIS buffer with Tween20, from Sigma) was used for blocking and TBS-T was used 
as washing buffer. The membrane was incubated 1 h with one of the nanobodies N87, 
N89, N93 or N00 that contain an EPEA tag at 1 mg/ml concentration, diluted in TBS-
T buffer. After washing the membrane three times for five minutes, anti-EPEA 
antibody coupled to biotin (ThermoFisher) was used as primary antibody, the 
membrane washed three times for five minutes and streptavidin coupled to 
horseradish peroxidase (ThermoFisher) applied as secondary antibody. The blot was 
developed using Super Signal West Pico Substrate (ThermoFisher) and Super Signal 
West Femto Substrate (ThermoFisher) in 1:10 ratio. The image was acquired with a 
ChemiDoc MP device (Bio-Rad). 
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Figure 9: The evaluation of linear or conformational binders via western blot 
The integral membrane protein (IMP) was transferred to a PVDF membrane 
(represented in grey) after SDS-PAGE. First, the membrane was incubated with a 
nanobody that contains the EPEA-tag. Then, an anti-EPEA-tag antibody coupled to 
biotin was applied as primary antibody and streptavidin coupled to horseradish 
peroxidase as secondary antibody. The blot was developed by Super Signal West Pico 
Substrate and Super Signal West Femto Substrate and imaged with a ChemiDoc MP 
device. 
2.2.3.3. Thermal stability analysis 
Nano differential scanning fluorimetry (nanoDSF) was used to assess the thermal 
stability of proteins and test possible protein-protein and protein-ligand interactions. 
In this method, the intrinsic signal from the proteins, mostly from tryptophan residues, 
is followed along a temperature scan. Upon thermal unfolding event, we can detect 
the change in the fluorescence signal from the tryptophan residues. The fluorescence 
at 330 nm and 350 nm is recorded over a temperature gradient scan from 20 to 90 °C 
with 1 °C per minute. From the ratio of 330 nm to 350 nm fluorescence signal plotted 
against the temperature, the thermal stability is read at the transition point. A shift in 
the thermal stability in the presence of an additional protein or ligand is interpreted as 
potential binding. The DtpA concentration was 0.5 mg/ml throughout all experiments, 
except stated otherwise. For the protein-protein interaction measurements, DtpA was 
mixed with nanobody in 1:1.2 molar ratio and incubated 1 h prior to measurements. 
For the protein-ligand interaction measurements, 18 µL of DtpA was mixed with 2 µL 
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of ligand (final ligand concentration was 5 mM). 10 µL of the solution was filled into 
a standard capillary (Nanotemper), which is placed into the Prometheus NT.48 device 
(Nanotemper) for the measurement using 20 % LED and 20 % MST power. The 
results were analyzed in GraphPad Prsim 5.0. 
2.2.3.3.1. RUBIC screen  
The thermostability of DtpA and DtpA-N00 complex was analyzed via nanoDSF 
method (Materials section 2.2.3.3) under different pH, buffer and salt conditions using 
the commercial RUBIC screen (Molecular Dimensions) (Boivin, Kozak, and Meijers 
2013). RUBIC screen was described initially for the thermofluor assay but is also 
compatible with the nanoDSF method. The conditions included in the RUBIC screen 
are listed in Appendix Table 17. 21 µL of RUBIC screen was mixed with 2 µL of 
DtpA (final concentration 0.2 mg/ml) and 2 µL DDM (final concentration 0.03 %), 
which was important to have enough detergent in the solution for the membrane 
protein integrity. The samples were loaded to the Prometheus NT.48 device and 
measured at 30 % LED and 20 % MST power. The results were analyzed in 
GraphPad Prism 5.0. 
2.2.3.4. Binding affinity measurements 
2.2.3.4.1. Microscale Thermophoresis (MST) without labeling 
The binding affinity of DtpA to the di-/tripeptides was measured by microscale 
thermophoresis using the Monolith NT.Labelfree device (Nanotemper). This method 
is based on the detection of intrinsic fluorescence of proteins mostly from the 
tryptophan residues within the protein. To measure the binding affinity, a 
concentration series of the ligand is mixed with the protein in glass capillaries. 
Infrared laser heats a spot within the capillary and the movement of the protein is 
tracked by fluorescence at 330 and 350 nm. The motion of the protein upon heat is 
dependent on its size, charge and hydration shell, which changes upon ligand binding. 
Plotting the ligand concentration against the fluorescence ratio at 330 nm to 350 nm at 
a given time point gives a ligand-binding curve and from the transition point a value 
equivalent to dissociation constant (Kd) is withdrawn. The advantage of the technique 
is that it requires a small volume of the protein and ligand as well as a very low 
concentration of the protein (in nM range); also, there is no need for labeling. 
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DtpA was initially diluted to 0.5 µM with assay buffer (100 mM HEPES, pH 7.5, 
150 mM NaCl, 0.03 % DDM). A dilution series of the substrate was prepared with the 
same buffer. 10 µL of DtpA was then mixed with 10 µL of the substrate dilution 
series and incubated for 10 min at room temperature before loading the samples in 
standard capillaries to the MST NT.LabelFree device. For the measurements with the 
DtpA-N00 complex, the concentration of DtpA was kept constant and a 1:1.2 molar 
ratio of N00 was added to DtpA and incubated for 1 h. As a negative control, the 
binding affinity of N00 alone, at 2 µM concentration, to selected peptides was 
measured under same conditions. The settings were 20 % LED and 20 % MST power. 
All measurements were performed in duplicates and the results were analyzed with 
GraphPad Prism 5.0. 
2.2.3.4.2. Microscale Thermophoresis (MST) with labelling 
The limiting factor of the label-free MST method is that some ligands contribute to 
the signal measured at 330 nm and 350 nm wavelengths, which prevents from 
detecting the binding effect, as it was the case for the drugs valganciclovir and 
valacyclovir. In these cases, the label-free method cannot be used and as an 
alternative, one can label the protein and use another wavelength for the 
measurements. DtpA has an uncleavable His-tag at the C-terminus, which was used 
for the labeling with the RED-tris-NTA kit (Nanotemper) according to the protocol of 
the manufacturer with small changes. The first change was the used buffer; instead of 
the advised buffer the assay buffer containing the detergent DDM (100 mM HEPES, 
pH 7.5, 150 mM NaCl, 0.03 % DDM) was used in all steps and second, the 
concentration of the protein was increased in relation to the dye due to the low 
binding affinity of the dye to the protein.  
DtpA was diluted to 1.6 µM and labeled with RED-tris-NTA dye according to the 
supplier’s protocol but with mentioned changes. 10 µL of the labeled DtpA was 
mixed with 10 µL of the ligand and incubated 10 min at room temperature. Monolith 
NT.115 device (Nanotemper) was used with the standard capillaries and 20 % LED 
and 20 % MST power settings. To compare the results from unlabeled and labeled 
DtpA, the binding affinity of the tripeptide AFA was measured in both systems. All 
measurements were performed in duplicates and the results were analyzed with 
GraphPad Prism 5.0. 
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2.2.3.5. In vivo AK-AMCA uptake and competition assay 
The transport activity of DtpA was investigated by the in vivo AK-AMCA uptake 
assay. AK-AMCA stands for β−AlaLys coupled to the fluorescent dye (7-amino-4-
methylcoumarin-3-yl) acetic acid by a peptide bond between the side chain amine 
group of lysine and the carboxyl group of the fluorescent dye (Figure 10). 
 
Figure 10: β-Ala-Lys-AMCA chemical structure 
 
DtpA transports AK-AMCA into the cell as well as hPepT1 and hPepT2 and the 
ligand selectivity of these proteins have been often characterized in vivo by the 
competition assay with this molecule. E. coli C41(DE3) cells containing the DtpA 
plasmid were grown in 5 mL LB medium supplemented with 0.1 mg/ml ampicillin to 
an OD600nm of 0.7. DtpA expression was induced by the addition of 0.2 mM IPTG, 
and was incubated for 3 h at 37 °C. The cell culture was then centrifuged for 3 min at 
3000 rpm and resuspended to a final OD600nm of 10 in the assay buffer (100 mM 
HEPES, pH 7.5, 150 mM NaCl, 5 mM glucose). 40 µL of cells, 40 µL of buffer, 
10 µL of AK-AMCA (final concentration 50 µM) and 10 µL of the competing ligand 
(final concentration 5 or 0.5 mM) were mixed in a 96-well plate and incubated for 
20 min at 37 °C shaking at 220 rpm. The reaction was stopped by adding 200 µL of 
ice-cold assay buffer and the cells were washed twice with the assay buffer. Finally, 
the cells were resuspended in 200 µL assay buffer and the fluorescence was measured 
with excitation at 350 nm and emission at 450 nm in an M1000 microplate reader 
(TECAN). All experiments were performed in triplicates. The results were 
normalized by the fluorescence value of the control, cells overexpressing DtpA 
incubated with AK-AMCA, and plotted as AK-AMCA uptake percentage. The 
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analysis was performed in Excel and GraphPad Prism 5.0. The IC50 values were 
extracted from the log(inhibitor) vs response curves in GraphPad Prism and the Ki 
value was calculated with the Cheng and Prusoff equation (see below) (Cheng and 
Prusoff 1973). 
Ki=
IC50
1+ [S]Km
 
 
2.2.3.6. In vivo crosslinking of DtpA and N00 
The in vivo binding of N00 to DtpA was investigated by a crosslinking experiment. 
The experiment was performed by Kim Bartels from EMBL Hamburg. DtpA was 
mutated with a UV inducible cross-linker at two positions separately. One position 
G53 was selected in proximity of the N00 binding site in the periplasmic side of DtpA 
and the second position F265 was selected on the cytoplasmic side of DtpA further 
apart from the N00 binding site as a negative control. The crosslinking protocol from 
Farrell et al. was followed (Farrell et al. 2005). The DtpA plasmid carrying the 
mutation and the amber suppression plasmid pEvol-pBpF, which was kindly provided 
by Prof. Henning Tidow from University of Hamburg, were co-transformed into E. 
coli C41(DE3) cells. The cells were grown in 100 mL TB buffer until the OD600nm 
reached 0.7 and the media was supplemented with 1 mM Tyr, 1 mM Trp, 1 mM p-
benzoyl-L-phenylalanine (pBpA) and 0.02 % arabinose. After 50 min incubation at 
37 °C and shaking at 220 rpm, the protein expression was induced by 0.2 mM IPTG 
and incubated for further four hours. The cells were harvested by centrifugation at 
4000 rpm for 12 min at 4 °C and resuspended in 20 mL lysis buffer (20 mM NaP, 
pH 7.5, 300 mM NaCl, 5 % glycerol, 15 mM imidazole and 0.5 mM TCEP). Then, 
the cells were disrupted by sonication two times 1 min, 0.5 s on/off rate and 30 % 
amplitude. The cells were centrifuged and resuspended again in 20 mL lysis buffer 
and mixed with 5 µL N00 at 13 mg/ml. Half of the sample was kept in a tube as UV 
negative control, whereas the other half was poured in a petri dish and shone UV light 
upon at 365 nm for 60 min. For both fractions, DtpA was purified from the membrane 
as described in Methods section 2.2.2.1 and western blot analysis was performed as 
described in Methods section 2.2.3.2, with the exception that a His Probe-HRP 
antibody was used to detect DtpA.  
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2.2.4. Structural biology methods 
2.2.4.1. Crystallization of DtpA 
2.2.4.1.1. Vapor diffusion method 
DtpA at 11 mg/ml concentration was mixed with N00 (13 mg/ml) in 1:1.2 molar ratio. 
The final concentration of DtpA was 8.5 mg/ml in the DtpA-N00 complex. For 
crystallization of DtpA without nanobodies, the sample at 11 mg/ml concentration 
was used. For crystallization trials with ligand, the ligand powder was weighed in a 
fresh tube and DtpA-N00 mix was added on top leading to 30-50 mM ligand 
concentration. The sample was incubated 1 h on ice and Intelli-plates (Art Robbins 
Instruments) were filled with the protein sample and reservoir solution in 1:1, 1:2 and 
2:1 ratio with a final volume of 300 nL using the liquid dispenser robot mosquito 
(ttplabtech). The initial crystallization screens are listed in Table 7. The conditions, in 
which initial crystals grew, were optimized with self-made screens using the scorpion 
screen builder (Art Robbins Instruments). The crystallization plates were stored in the 
protein crystallization imager Rock Imager-1000 (Formulatrix) either at 19 or 4 °C 
and frequent images were taken automatically following the crystallization process. 
To test the crystals at the beamlines, crystals were fished out of the crystallization 
drop with a LithoLoop (Molecular Dimensions) of fitting size to the crystal size and 
stored flash frozen until beam time.  
2.2.4.1.2. Lipidic cubic phase method 
For LCP crystallization, the protocol from Aherne et al. was followed (Aherne, 
Lyons, and Caffrey 2012). DtpA, at 11 mg/ml, was mixed the lipid 1-(7Z- 
pentadecenoyl)-rac-glycerol (MAG 7.8) in equal volumes. The lipid was pre-warmed 
on a thermoblock for 3 min at 45 °C and loaded on a pre-warmed Hamilton gastight 
syringe for mixing. The DtpA solution was loaded on another syringe, which was then 
connected to the syringe with the lipid via an LCP syringe coupler (ttplactech). 
Pushing the content in the syringes from one side to the other 30 to 50 times until the 
content was transparent and homogenous mixed DtpA and the lipid. The DtpA-lipid 
mix was moved to one syringe and the other syringe with the coupler was replaced 
with a mosquito LCP needle (ttplabtech). The syringe was connected to the liquid 
dispenser robot mosquito (ttplabtech) and 50 nL mesophase and 800 nL precipitant 
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solution were added on a Laminex UV plastic base with wells of 100 µm depth 
(Molecular Dimensions). The plate was sealed with a Laminex UV plastic 
200-micron film cover (Molecular Dimensions) and stored in the protein 
crystallization imager Rock Imager-1000 (Formulatrix) at 19 °C. Frequent images 
were taken automatically following the crystallization process and the plate was also 
manually inspected under microscope. 
2.2.4.2. Data collection and processing 
Several hundreds of crystals were screened for DtpA-N00 complex in ligand-free or 
ligand-bound state throughout this project. Mostly, the beamlines P1318 and P14 
operated by EMBL Hamburg at the PETRA III storage ring (DESY, Hamburg, 
Germany) were used but during shutdown times the ID23-1 (Nurizzo et al. 2006) and 
ID30B (McCarthy et al. 2018) at ESRF (Grenoble, France) were visited or crystals 
sent to ID30A-1/MASSIF-1 at ESRF (Grenoble, France) for automatic data collection 
(Bowler et al. 2015). The parameters for data collection were typically 0.1 to 0.2 ° 
oscillation range, 0.05 to 0.1 s exposure time, 100 % transmission, 1800 to 3600 
images covering 180 to 360 ° of the crystal and the detector distance at 2.0 to 2.5 Å 
resolution in the corners. 
The collected diffraction data was indexed and integrated by XDS (Kabsch 2010). 
Based on the I/σI, CC1/2 and completeness values the highest resolution limit was 
decided. For all reported structures a single crystal was used to determine the 
structure but scaling three to five datasets from different crystals was tested, which 
did not improve the statistics or the electron density after molecular replacement and 
one cycle of refinement. The scaling of the data was performed using XSCALE, 
followed by the conversion of the file format to mtz format via XDSCONV. 
Molecular replacement was performed using the Phaser program from the Phenix 
suite (Adams et al. 2010; McCoy et al. 2007). Initial molecular replacement tests with 
at the time available POT structures alone were not successful. Finally, the phases 
could be estimated by providing two models: DtpD structure (PDB id: 4Q65) 
modified to a polyalanine chain with loops removed and an unpublished nanobody 
structure, which I had previously solved in the scope of another project (data not 
shown). The LLG and TFZ scores were evaluated for choosing a good molecular 
replacement solution (Oeffner et al. 2013). The refinement was performed in iterative 
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cycles of the phenix.refine tool in Phenix suite with varying parameters at different 
stages and manual building of the structure in Coot (Emsley and Cowtan 2004). For 
the initial refinement strategy, the XYZ coordinates, real space and group B-factors 
were selected, the final cycles the TLS groups and optimize X-ray/stereochemistry 
and -/ADP weights were also included. For both diastereomers of valganciclovir and 
the DDM molecule, pdb and cif files were generated in eLBOW of Phenix suite 
(Moriarty, Grosse-Kunstleve, and Adams 2009), which were used in the refinement 
steps. The final models were validated by MolProbity (Chen et al. 2010; Davis et al. 
2007) and pdb-redo server (Joosten et al. 2014). The determined structures were 
provided to the Protein Data Bank (PDB), which will be accessible upon publication:  
• DtpA-N00 complex in MES buffer, PDB id: 6GS1 
• DtpA-N00 complex in glycine buffer, PDB id: 6GS7 
• DtpA-N00 in complex with valganciclovir, PDB id: 6GS4 
 
2.2.4.3. Structural analyses  
The structures were inspected and prepared for figures in PyMOL (Delano 2002). The 
DtpA-N00 and DtpA-valganciclovir interactions were analyzed by LigPlot (Wallace, 
Laskowski, and Thornton 1995; Laskowski and Swindells 2011) and manual 
inspection in PyMOL. For the ligand-binding site cavity analysis POVME 2.0 
(Durrant, de Oliveira, and McCammon 2011; Durrant et al. 2014) was used. Here, the 
tested protein structures were first all aligned to DtpA-N00 structure (PDB id: 6GS4) 
in PyMOL. The position of the Cα atom of the valine residue in valganciclovir was 
selected due to its central position in the investigated binding pocket. The cavity 
volume with a radius of 4 and 7 Å was calculated using the software. 
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3. Results 
3.1. Protein expression and purification 
3.1.1. Expression and purification of DtpA 
For the characterization of DtpA and crystallization experiments, wild type (WT) 
protein and mutants were expressed and purified as described in the Methods section 
2.2.2.1. The results from the DtpA WT purification are shown in Figure 11 and are 
representative for the purification of the mutants as well. Typically, 20 g cell pellet 
(wet weight) was harvested from 1 L cell culture of E. coli cells and up to 5 mg DtpA 
was purified. The protein purity was evaluated by SDS-PAGE analysis throughout the 
purification process. Despite the monodisperse protein profile in the gel filtration 
chromatogram, the protein was not completely pure; there were additional 
contaminants of high molecular weight that were not possible to eliminate. Therefore, 
an optimization of the purification protocol coupled to the nanobody 00 (N00) was 
developed to improve the overall purity of the sample (see section 3.1.3). 
 
 
Figure 11: Purification of DtpA 
(a) Gel filtration chromatogram. The peak corresponding to DtpA is highlighted with 
a red box. (b) Coomassie stained gel of all purification steps.  
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3.1.2. Expression and purification of the nanobodies 
Four nanobodies, nanobody 87, -89, -93 and -00, were generated against DtpA as 
crystallization chaperones. Els Pardon and Jan Steyaert from the Vrije University 
Brussels performed the nanobody generation with the provided detergent-solubilized 
DtpA according to the described protocol in Pardon et al. (Pardon et al. 2014). I have 
received the plasmids of the nanobodies and expressed and purified the nanobodies as 
described in Methods section 2.2.2.2. As an example of the purification process, the 
chromatograms of the nanobody 00 (N00) purification are shown in Figure 12, which 
are representative for other nanobody purifications as well. The nanobody gene 
construct contains a C-terminal EPEA-tag (EPEA stands for GluProGluAla), 
therefore the nanobodies were purified on an affinity column (CaptureSelect™ C-tag 
affinity matrix) directed against the EPEA-tag.  
 
 
Figure 12: Purification of nanobody 00 
(a) CaptureSelect affinity chromatogram. (b) Gel filtration chromatogram with the 
peak corresponding to N00 marked with a red box. (c) Coomassie stained gel with all 
purification steps. 
The purity of the sample was high. The protein yields were ca. 15 mg from 1 L cell 
culture starting material. The purified nanobody sample was mixed in 1:1.2 molar 
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ratio with DtpA for functional characterization and crystallization experiments based 
on the observation of 1:1 binding mode and to have a slight excess of nanobody to 
DtpA. 
3.1.3. DtpA purification coupled to N00 
Combining the purification of DtpA to the purification of N00 a new purification 
protocol was developed. All steps were followed individually for DtpA and N00 as 
described until DtpA was applied to the second ultracentrifugation step and N00 was 
loaded on the CaptureSelect affinity beads (Figure 13). Instead of applying DtpA to 
Ni-IMAC beads, it was applied to the CaptureSelect affinity beads, which were pre-
loaded with N00 and washed with the gel filtration buffer of DtpA containing 0.03 % 
DDM. After elution of the complex, the TEV cleavage and gel filtration steps were 
performed as described in Methods section 2.2.2.3. 
 
 
Figure 13: Purification of DtpA coupled to N00 
(a) N00 is loaded on the CaptureSelect affinity beads. (b) DtpA is loaded on 
CaptureSelect beads after the second ultracentrifugation step and eluted together with 
 57 
N00. (c) Gel filtration chromatogram of DtpA-N00 complex. The peak corresponding 
to the complex is marked with a red box. (d) Coomassie stained gel from all 
purification steps. 
A highly pure sample of the DtpA-N00 complex was achieved but the yield was with 
3 mg from 1 L cell culture starting material lower than the original DtpA purification 
protocol (5 mg from 1 L cell culture). It is possible that the impurities in the original 
purification method led to an overestimation of the protein concentrations. 
Nevertheless, the crystallization attempts were more successful with the original 
DtpA purification protocol and mixing DtpA and N00 just before setting up 
crystallization plates; therefore, the DtpA purification coupled to N00 was not 
optimized further.  
3.2. Complex formation of DtpA and nanobodies 
3.2.1. DtpA and nanobody interaction monitored by analytical gel 
filtration assay 
The complex formation of DtpA and nanobodies was analyzed by analytical gel 
filtration chromatography (Methods section 2.2.3.1). Individual protein runs were 
compared to the potential complexes formed between DtpA and the nanobodies. 
Furthermore, combinations of two nanobodies were tested with DtpA to investigate a 
possible cooperative binding of multiple nanobodies. Additionally, a nanobody 
generated against another membrane protein (N21) was used as a negative control. 
The evaluation of complex formation chromatograms can be summarized in terms of 
three major observations: (i) the DtpA peak is shifted to a shorter retention time due 
to the slightly larger size of the complex relative to DtpA alone, (ii) the absorption 
signal of the DtpA peak is increased due to the contribution of the nanobody and (iii) 
the absorption signal of the nanobody peak is strongly reduced, because the nanobody 
no longer elutes at that retention time but in complex with DtpA. All nanobodies 
against DtpA form a complex with DtpA as evident on the chromatograms but no 
complex formation is observed for with N21 (Figure 14). There was no binding 
observed for any combination of two nanobodies (data shown only for the 
combination of N00 and N87). Such a binding would suggest that two nanobodies 
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stabilize the same conformation but bind on distinct sites to DtpA. The absence of the 
binding could be interpreted in two ways. Either the nanobodies bind to different 
conformations of DtpA or they bind to the same site on DtpA. 
 
 
Figure 14: Analytical gel filtration profiles of DtpA and nanobodies 
 (a-d) The chromatograms of DtpA and the four nanobodies, which were generated 
against DtpA are plotted with DtpA alone in black, the nanobody alone in blue and 
the complex in red. Arrows highlight the change in absorbance signal between the 
DtpA/nanobody alone and the complex. (e) A negative control was included in the 
experiment using N21, which is a nanobody generated against another membrane 
protein. (f) An exemplary curve for the testing of two nanobodies (N00 and N87) 
incubated with DtpA at the same time (in cyan). The curves of DtpA-N00 (red), 
DtpA-N87 (brown), N00 alone (dark blue), N87 alone (blue) are included for 
comparison. 
3.2.2. Thermal stability of DtpA with nanobodies 
The complex formation of DtpA and nanobodies were investigated in addition to the 
analytical gel filtration assay with the nano differential scanning fluorimetry 
(nanoDSF) method (Methods section 2.2.3.3). Here, the intrinsic fluorescence of the 
protein from mostly tryptophan residues are tracked over a temperature gradient from 
20 to 85 °C. A value for the thermal stability (also called the melting temperature, Tm) 
of the protein is obtained from the transition point in the fluorescence ratio 
350 nm/330 nm plotted against the temperature.  
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The thermal stability of DtpA and nanobodies were measured individually and in 
combination. All nanobodies generated against DtpA led to a significant thermal 
stabilization. The melting temperature of DtpA was increased by 10 to 18 °C, which 
was interpreted as complex formation (Figure 15). The negative control, N21, does 
not thermally stabilize DtpA, which is interpreted as no interaction. Furthermore, 
higher molar ratios of DtpA to nanobodies, such as 1:2 and 1:3, were tested but these 
did not show any further stabilization effect (data not shown). Therefore, we expect a 
1:1 binding mode. 
 
 
Figure 15: Thermal stabilization effect of nanobodies on DtpA 
(a) The fluorescence ratio between 350 nm and 330 nm is plotted for DtpA alone 
(black) and DtpA-N00 complex (red) across the temperature gradient. (b) Thermal 
stability of DtpA (black), DtpA-nanobody complexes (red) and nanobody on its own 
(blue). N21 is a negative control. The error bars indicate the standard deviation 
calculated from two experiments. 
3.2.3. Evaluation of conformational or linear binders 
One of the challenges while generating nanobodies against membrane proteins is that 
often generated nanobodies would recognize linear epitopes, namely parts of the 
unfolded protein. Most likely because the membrane protein would start to unfold 
after the immunization of the lama and the selection process for the nanobodies would 
be then based on the partially unfolded protein. For using nanobodies as 
crystallization chaperones, it is crucial to have conformational binders, namely 
nanobodies binding and stabilizing the folded protein. The binding mode of the 
nanobodies was tested on a western blot analysis as described in the Method section 
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2.2.3.2. Proteins (DtpA, DtpC which was used as a negative control, and N00, 
positive control) were run on gel electrophoresis under denaturing conditions (SDS 
PAGE) and were then transferred to a PVC membrane and incubated with one of the 
four nanobodies (N87, -89, 93 and 00) for 1 h. After wash steps, the membrane was 
incubated with a primary antibody against the EPEA-tag of the nanobodies coupled to 
biotin and a secondary antibody, streptavidin coupled to horseradish peroxidase. On 
the developed membrane, only a band corresponding to the nanobody could be 
observed in the positive control lane loaded with N00 (Figure 16). The absence of 
bands in other lanes is interpreted as all nanobodies being conformational binders and 
they do not bind to DtpA (or DtpC) in the SDS treated/denatured form. This finding is 
also supported by the analytical gel filtration and thermal stability experiments, as 
they are also based on a conformational binding of the nanobody to DtpA. 
 
 
Figure 16: Evaluation of the conformational or linear binding mode 
DtpA, DtpC (as negative control) and N00 (as positive control) were loaded on a gel 
under denaturing conditions and transferred to a PVC membrane. The membrane was 
incubated with one of the four nanobodies (N87, N89, N93 or N00) and antibodies 
against nanobodies were used to detect, if the nanobodies could bind to denatured 
DtpA. No bands were observed in the DtpA lanes but only in the positive control lane 
loaded with a nanobody (N00). 
3.2.4. In vivo AK-AMCA uptake in cells co-expressing DtpA and N00 
With the previous experiments, the DtpA-nanobody interaction was shown with the 
purified and detergent-solubilized DtpA, which was necessary for crystallization. The 
two methods presented here and in the next section were developed to investigate the 
binding of N00 to DtpA, while DtpA was still in the cell membrane. Thereby, we can 
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evaluate if the determined DtpA-N00 structure (Results section 3.5) represents a 
biologically relevant state. 
The AK-AMCA uptake assay (Methods section 2.2.3.5) was used for the in vivo 
characterization of DtpA and N00 binding. Cells overexpressing DtpA and co-
expressing DtpA and N00 were tested in parallel and the cells co-expressing DtpA 
and N00 had only 25 % of AK-AMCA uptake relative to the cells overexpressing 
DtpA only (Figure 17). We concluded from this experiment that N00 binds to DtpA in 
its biological environment, the native membrane. 
 
 
Figure 17: AK-AMCA uptake of DtpA and DtpA-N00 co-expressing cells 
The AK-AMCA uptake assay was performed with cells overexpressing DtpA and 
DtpA co-expressed with N00 and the results were normalized by the uptake of cells 
overexpressing DtpA only. The error bars indicate the standard deviation calculated 
from three experiments. 
3.2.5. In vivo crosslinking of DtpA and N00 
Second approach to characterize N00 binding to DtpA in vivo was based on 
crosslinking, which was performed by Kim Bartels (EMBL Hamburg) in 
collaboration as described in Methods section 2.2.3.6. The UV inducible cross-linker 
was introduced in two positions within DtpA as an unnatural amino acid. One site was 
selected in direct proximity to the N00 binding site (G53) and one site in a distant 
position on the cytoplasmic side of the protein (F265) (Figure 18). DtpA containing 
the unnatural amino acid was overexpressed in E. coli and incubated with N00 after 
cell lysis with and without UV treatment in parallel. By western blot, we could see a 
band corresponding to the crosslinked DtpA-N00 complex, which was visible only 
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with the G53 mutant after UV treatment and not in the control lanes (Figure 18). With 
this experiment, we could confirm that N00 can bind DtpA, while it is still in the cell 
membrane. 
 
Figure 18: In vivo crosslinking of DtpA and N00 
(a) The overall structure of DtpA (wheat) and N00 (pink) with the mutation sites, G53 
and F265, highlighted in red. (b) E. coli cells overexpressing DtpA mutants with the 
unnatural amino acid were incubated with N00 after cell lysis and treated with UV 
light. On a western blot analysis, the crosslinking results were analyzed by the 
occurrence of a band corresponding to the DtpA-N00 complex. 
3.3. Protein characterization 
3.3.1. Thermal stability of DtpA at different conditions 
As a preliminary step towards functional as well as crystallization experiments, the 
effect of pH, buffer, and salt on DtpA was investigated with the nanoDSF method 
(Methods section 2.2.3.3) using the commercial RUBIC screen (Methods section 
2.2.3.3.1). The thermal stability of DtpA ranged from 44 to 53 °C in the tested 
conditions (Figure 19). 
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Figure 19: Heatmap of RUBIC screen results for DtpA and the conditions 
(a) The results from the RUBIC screen for DtpA are presented as a heat map with the 
lowest thermal stability in °C colored in red and the highest in green. (b) Conditions 
used in the RUBIC screen. The RUBIC screen consists of buffer and pH screens 
without NaCl (row A and B, in orange) and with 250 mM NaCl (row C and D, in 
yellow), followed by a pH range test using the SPG buffer (row E, in lilac) and 
selected buffers at different concentrations and constant pH (row F, in brown tones). 
Then, the effect of salt concentration from 50 mM to 1 M is tested for two buffers at 
constant concentration and pH (row G, in grey tones). Buffer combinations and effect 
of imidazole concentration is also included (row H, in blue tones). 
pH had the strongest effect on DtpA stability, with the highest stability at pH 4.5 to 
6.0 and destabilization at higher pH values (Figure 20). Different buffers in this pH 
range were tested in presence and absence of 0.2 M NaCl. In general, salts are often 
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included in buffers because of their stabilizing effect on the proteins. Nevertheless, in 
case of DtpA 0.2 M NaCl had a slightly destabilizing effect in some of the pH and 
buffer conditions. Sodium phosphate (NaP) buffer at pH 7.5 was used in initial 
purification experiments. With this screen, it was evident that NaP is a destabilizing 
buffer. More optimal buffers are TRIS and HEPES (Figure 20); therefore, the 
purification was continued with HEPES buffer at pH 7.5.  
 
 
Figure 20: Thermal stability of DtpA in different conditions 
(a) The effect of pH from 4.0 to 10.0 was tested as well as (b) a set of different buffers 
spanning the same pH range in presence and absence of salt (0.2 M NaCl). 
3.3.2. Thermal stability of DtpA-N00 complex at different conditions 
The thermal stability of DtpA-N00 complex was measured as described for DtpA 
above. The DtpA-N00 complex is overall more stable than DtpA as mentioned in 
section 3.2.2 with the melting temperatures ranging from 48 to 67 °C in the RUBIC 
screen (Figure 21). The thermal stability in position H5 was not possible to determine 
due to a technical problem, most likely due to air bubbles in the capillary. 
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Figure 21: Heatmap of RUBIC screen results for DtpA-N00 complex 
The results from the RUBIC screen for DtpA-N00 complex are presented as a heat 
map with the lowest thermal stability in °C colored in red and the highest in green. 
n.d. stands for not determined due to an error during the measurements. 
Interestingly, the DtpA-N00 complex has a different pH dependency than DtpA. The 
DtpA-N00 complex is stable from pH 5.5 to 10.0 and is only destabilized at lower pH 
values (Figure 22). This is on the contrary to DtpA, which is stable at lower pH and 
was destabilized at higher pH values (Figure 20). The effect of salt is more 
pronounced in the DtpA-N00 complex, possibly due to the destabilizing effect of salt 
on the complex. Almost for all tested buffer and pH combinations the presence of 
0.2 M NaCl lowers the thermal stability by a few °C (Figure 22). The choice of buffer 
does not make a difference but the change in pH is affecting the thermal stability of 
the complex. Overall, DtpA-N00 is very stable over a wide range of pH values, which 
facilitates the crystallization of the complex. 
 
 
Figure 22: Thermal stability of DtpA-N00 complex in different conditions 
(a) The effect of pH from 4.0 to 10.0 was tested as well as (b) a set of different buffers 
spanning the same pH range in presence and absence of salt (0.2 M NaCl). 
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3.4. Ligand selectivity 
3.4.1. Thermal stability analysis with the ligand library 
The ligand selectivity of DtpA was so far tested by in vivo uptake and competition 
assays with a limited number of di-/tripeptides and drugs (Weitz et al. 2007; Prabhala 
et al. 2017). In our group, we have established a fast method to screen the binding of 
ligands in vitro consuming only small amounts of purified protein relative to the 
conventional protein-ligand binding methods, such as the isothermal titration 
calorimeter. In this assay using the nanoDSF technique, a possible interaction of 
DtpA with the added ligand can be observed as an increase of the thermal stability. 
The ligand library containing eighteen dipeptides, ten tripeptides and seven drugs was 
tested for DtpA. The selection of the ligands was based on the criteria that they were 
water soluble and commercially available. The following observations were made 
from the results shown in Figure 23: (i) All tripeptides, except GlyGlyHis, more than 
half of the dipeptides and two drugs, valacyclovir and valganciclovir, from the library 
stabilize DtpA. (ii) The hydrophobic and aromatic residues are more stabilizing than 
charged residues in the ligand. (iii) Ligands with glycine residues have little to no 
stabilization effect. A box plot representation was prepared by Jan Strauss from 
EMBL Hamburg with the thermal stability results, which were subtracted from 
control (water) and summarized for tripeptides and dipeptides (figure 9b). The median 
for tripeptides is 7.1 °C and for dipeptides 2.4 °C (p = 0.035) concluding that 
tripeptides have a significantly higher stabilization effect relative to dipeptides on 
DtpA. The ligands with the highest stabilization effect were further investigated with 
concentration dependent thermal stability and binding affinity measurements as 
described in the following sections. 
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Figure 23: Thermal stability of DtpA with the ligand library 
(a) The potential binding of the ligands was tested based on the shift of thermal 
stability. The ligand concentration was 5 mM. The error bars indicate the standard 
deviation calculated from three experiments. (b) Box plot analysis of the same results 
grouped for tripeptides and dipeptides. The 95 % quartile is drawn in green for 
tripeptides and orange for dipeptides with the lines above and underneath representing 
the upper and lower extremes. The outliers are shown as dots. 
3.4.2. Concentration dependent thermal stability measurements 
Following the thermal stability assay with the ligand library, the tripeptide, 
LeuLeuAla and the dipeptide, AlaLeu, was selected from the ligands with the highest 
stabilization effect and their stabilization was validated by a concentration dependent 
assay using the nanoDSF method (Methods section 2.2.3.3). In each case, a 
concentration dependent stabilization effect was observed (Figure 24). This effect was 
stronger for DtpA than for DtpA-N00 complex, which has a much higher thermal 
stability, as expected. It is indeed impressive that DtpA-N00 complex reaches a 
thermal stability of 74 °C in the presence of 10 mM LeuLeuAla and 70 °C already at 
0.3 mM LeuLeuAla. We concluded that not only DtpA but also DtpA-N00 complex 
binds to LeuLeuAla and AlaLeu.  
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Figure 24: Concentration dependent thermal stabilization effect 
The thermal stabilization effect was validated for a tripeptide, LeuLeuAla in green, 
and a dipeptide, AlaLeu in orange with DtpA and DtpA-N00 complex. The error bars 
indicate the standard deviation calculated from two experiments. 
3.4.3. Acyclovir derivates 
Human PepT1 and PepT2 can transport the prodrugs valganciclovir and valaciclovir 
but not the original drugs ganciclovir or acyclovir (Guo et al. 1999; Sugawara et al. 
2000). After observing the thermal stabilization effect of valganciclovir and 
valacyclovir on DtpA, we have tested the thermal stabilization effect of ganciclovir, 
acyclovir and penciclovir, which is a similar drug to the other two. All three drugs are 
poorly water-soluble and therefore were solubilized in 100% DMSO. As a control, 
DtpA was mixed with 100% DMSO in the same ratio as with the ligands. The final 
concentration of DMSO was 5 % in all samples. The addition of the drugs did not 
change the thermal stability (Figure 25) in contrast to the stabilizing effect of 
valganciclovir and valacyclovir (Figure 23). Therefore, we conclude that there is no 
interaction of DtpA with ganciclovir, acyclovir or penciclovir as suggested for 
hPepT1 as well. Noticeably, the thermal stability of DtpA is slightly lower in presence 
of 5 % DMSO. 
 69 
 
 
Figure 25: Thermal stability of DtpA in presence of acyclovir derivates 
The thermal stabilization effect of the acyclovir, ganciclovir and penciclovir were 
tested. All samples, including control, are in the presence of 5 % DMSO. The error 
bars indicate the standard deviation calculated from three experiments. 
3.4.4. Binding affinity measurements of peptide and drugs with DtpA 
and the DtpA-N00 complex 
After testing the ligand library based on the change of thermal stability (Figure 23), 
the ligands with the strongest effect were selected for further investigation. The 
binding affinity of the selected ligands to DtpA or DtpA-N00 complex was measured 
with microscale thermophoresis (MST) as described in Methods section 2.2.3.4. The 
label-free setup of MST is based on the detection of intrinsic fluorescence of proteins, 
mainly from tryptophan residues. The movement of the protein is followed within a 
small temperature gradient induced by an infrared laser, and the movement is 
dependent on the size, charge and hydration shell of the molecule, which changes 
upon ligand binding. The normalized fluorescence at a selected time point is plotted 
against the ligand concentration resulting in a ligand-binding isotherm and from the 
transition point a value equivalent to the dissociation constant (Kd) can be extracted. 
The advantage of the technique is that it requires only small volumes and a very low 
concentration of the protein (in nM range), also there is no need for labeling but the 
limiting factor is possible fluorescence signal from the ligands as observed in the case 
of valganciclovir and valacyclovir. Therefore, the measurements with the two drugs 
were performed with the Monolith NT.115 device after labeling the C-terminal His-
tag of DtpA with the Monolith NT His-Tag labeling kit RED-tris-NTA (Methods 
Ga
nc
icl
ov
ir
Ac
yc
lov
ir
Pe
nc
icl
ov
ir
co
ntr
ol
40
45
50
Th
er
m
al
 s
ta
bi
lit
y 
[º
C
]
 70 
section 2.2.3.4.2). Here the fluorescence signal from the RED dye was followed as 
opposed to the intrinsic tryptophan signal. No fluorescence was detected from 
valganciclovir or valacyclovir at the measured wavelength. The results for all tested 
ligands are shown in Table 15 and Figure 26. 
 
Table 15: Binding affinity results for di-/tripeptides and the two drugs 
 
DtpA DtpA-N00 
Ligands Kd [µM] Kd [µM] 
valganciclovir 76 ± 16* 113 ± 29* 
valacyclovir 60 ± 13* 67 ± 15* 
LLA 58 ± 10 59 ± 10 
AL 491 ± 112 104 ± 21 
ALA 185 ± 52 112 ± 27 
AFA 113 ± 24, 33 ± 3* 71 ± 13 
AF 106 ± 22 47 ± 13 
LL 99 ± 27 45 ± 9 
LA 564 ± 250 140 ± 39 
*These measurements were performed with labeling the His-tag of DtpA, whereas the 
others in a label free approach.  
 
The highest affinity was observed for the tripeptide LeuLeuAla, which is also the 
most thermal stabilizing ligand. Overall, tripeptides had higher binding affinities 
relative to dipeptides, which is in good agreement with the results from thermal 
stability experiment. To compare the label-free and labeled method, the tripeptide 
AlaPheAla was measured using both techniques and indeed there was a 3-fold 
difference with the labeled method showing a higher binding affinity. Therefore, one 
needs to be careful while comparing the binding affinity of the drugs with the di-
/tripeptides. Overall, they are all in the low to medium µM range. Few ligands, which 
did not show any thermal stabilization effect, were also measured with this technique 
but no binding affinity could be determined for any of these ligands (data not shown). 
Following the observation from concentration dependent thermal stabilization effect 
of the ligands on DtpA and DtpA-N00 complex, the binding affinity of the same set 
of ligands was measured with DtpA-N00 complex. In most cases, the binding affinity 
was similar (2-fold change or less). Nevertheless, in two cases, with AlaLeu and 
LeuAla, there was a 5-fold difference with the DtpA-N00 complex having a higher 
binding affinity relative to DtpA. As a control, the binding affinity of N00 alone with 
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the ligands LeuLeuAla and AlaLeu were measured and no binding could be detected 
(Figure 26). 
 
Figure 26: Binding affinity curves for di-/tripeptides and the two drugs 
 (a) Binding affinity of DtpA and DtpA-N00 complex to the ligands LeuLeuAla, 
AlaLeu, AlaPheAla, AlaLeuAla, LeuLeu AlaPhe and LeuAla was measured by the 
labelfree method. N00 was measured only with LeuLeuAla and AlaLeu (b) The 
binding affinity of valganciclovir and valacyclovir was measured with the same set of 
ligands after labeling DtpA. The error bars indicate the standard deviation calculated 
from two measurements. 
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3.4.5. In vivo uptake and competition assay with the ligand library 
The ligand selectivity of DtpA was studied previously by other groups using the in 
vivo AK-AMCA (β-Ala-Lys-N-7-amino-4-methylcoumarin-2-acetic acid) uptake and 
competition assay (Weitz et al. 2007). For this method as described in detail in 
Methods section 2.2.3.5, cells overexpressing DtpA are incubated with the dipeptide 
mimetic coupled to a fluorescent dye (AK-AMCA), DtpA takes up the fluorescent 
molecule into the cell and the fluorescence trapped in the cells is measured by a 
fluorometer. For the competition experiment, a ligand is added along with AK-
AMCA, which competes with its uptake. Thereby, the lower the AK-AMCA uptake 
is, the higher is the competition from the ligand, which is interpreted as binding and 
possibly transport of the ligand by DtpA. I have established this method in our lab to 
compare it with the results from the thermal stability and binding affinity 
measurements that are both in vitro assays. At 5 mM ligand concentration all 
tripeptides, almost all dipeptides and from the drugs valacyclovir and valganciclovir 
lead to strong competition (Figure 27). The dipeptides, which have a slightly lower 
competition rate (20-60 % AK-AMCA uptake rate), contain either charged residues in 
the N-terminal and C-terminal position or a glycine residue. To compare the 
competition rate of the ligands within the library, the concentration was reduced to 0.5 
mM (Figure 27). At this concentration, we observe a similar trend compared to the 
results from the thermal stability assay (Figure 23). Overall, the tripeptides show a 
stronger competition relative to the dipeptides and the ligands with hydrophobic 
residues are better competitors than the ligands with charged residues. From the drug 
library, valacyclovir and valganciclovir show a similar competition rate to di-
/tripeptides.  
A box plot analysis was performed by Dr. Jan Strauss from EMBL Hamburg based on 
the results at 0.5 mM ligand concentration (Figure 27) for comparing the tripeptides 
and dipeptides. The AK-AMCA competition rate was calculated by subtracting the 
uptake rate from 100 %. The AK-AMCA competition rate of tripeptides have a 
median of 68 % whereas the dipeptides only 53 % (p=0.005). This is in good 
agreement with the results from the thermal stability data (Figure 23). 
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Figure 27: AK-AMCA competition assay with the ligand library 
AK-AMCA competition assay with the ligand library at (a) 5 mM and (b) 0.5 mM. 
The error bars indicate the standard deviation calculated from three experiments. (c) 
Box plot analysis based on the results at 0.5 mM ligand concentration and subtracted 
from 100 % for better comparison to the thermal stability results. The 95 % quartile is 
drawn in green for tripeptides and orange for dipeptides with the lines above and 
underneath representing the upper and lower extremes. The outliers are shown as 
dots. 
3.4.6. Concentration dependent in vivo competition assay 
Next, the tripeptide, LeuLeuAla, and the dipeptide, AlaLeu, as well as the two drugs, 
valacyclovir and valganciclovir, were further investigated by concentration dependent 
in vivo AK-AMCA competition measurements. The IC50 and Ki values were 
calculated from the curve as described in Methods section 2.2.3.5. All IC50 and Ki 
values are in low to mid µM range with the lowest value for LeuLeuAla. This is in 
good agreement with the in vitro binding affinity (Kd) values (Table 15, Figure 26) 
and the described values from the literature (Weitz et al. 2007).  
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Figure 28: Concentration dependent AK-AMCA competition assay 
Concentration dependent AK-AMCA competition assay with (a) LeuLeuAla, (b) 
AlaLeu, (c) valganciclovir and (d) valacyclovir. The curve is fitted by log(inhibitor) 
vs response equation in GraphPad Prism v5 and the error bars indicate the standard 
deviation calculated from three experiments. 
3.5. Crystallization and structure determination 
Crystallization was performed to determine the structure of DtpA in the road of 
understanding its ligand selectivity and drug transport capability. We used the vapor 
diffusion and lipidic cubic phase crystallization methods to solve the structure, 
although only the former method yielded crystals. Three structures were determined 
and uploaded in the Protein Data Bank (PDB) as part of this thesis: DtpA-N00 
complex in MES buffer (PDB id: 6GS1), DtpA-N00 complex in glycine buffer (PDB 
id: 6GS7) and DtpA-N00 in complex with valganciclovir (in glycine buffer) (PDB id: 
6GS4). The first two are ligand-free structures determined in different crystallization 
conditions and the third one is co-crystallized with valganciclovir. This is the first 
structure of a proton-dependent oligopeptide transporter (POT) in complex with a 
commercial drug. 
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3.5.1. DtpA-N00 complex in MES buffer 
To solve the structure of DtpA, sitting drop vapor diffusion (Methods section 
2.2.4.1.1) and lipidic cubic phase (Methods section 2.2.4.1.2) crystallization methods 
were performed. No initial crystals for DtpA were observed with the used commercial 
crystallization screens in both methods. Nanobodies were generated against DtpA as 
crystallization chaperones and all four generated nanobodies could bind and stabilize 
DtpA as shown in section 3.2.2. Furthermore, initial crystals were observed for DtpA 
with all four nanobodies with the vapor diffusion method using the same commercial 
screens but not using the lipidic cubic phase method. Optimization screens were 
prepared for several conditions including at least one condition for each DtpA-
nanobody combination. Although crystals could be obtained in most cases, only the 
crystals of DtpA-N00 complex significantly improved through the optimization cycles 
and yielded diffraction in higher resolution ranges. The crystals to determine the first 
structure of the DtpA-N00 complex (in MES buffer) grew in 0.02 M MgCl2, 0.1 M 
MES, pH 6.5, 32 % PEG 600 condition. The crystals first appeared on day 14 and 
grew until day 28 (Figure 29) and were flash frozen without an additional 
cryoprotectant, because the high concentration of PEG 600 was acting as a natural 
cryoprotection.  
 
 
Figure 29: Crystals of DtpA-N00 complex grown in MES buffer condition 
Crystals of DtpA-N00 complex grown in the MES buffer condition are either needles 
or thin plates. Picture was taken on day 28. One of these crystals led to the first 
structure of DtpA. 
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The diffraction data were collected at the fully automated MASSIF-1 (ID30A-1) 
beamline at the European Synchrotron Radiation Facility (ESRF, Grenoble France) 
under cryo conditions (Bowler et al. 2015). XDS and XSCALE packages were used 
for data processing (Kabsch 2010). The space group was identified as P212121 and the 
unit cells were 55.46, 120.72, 63.33 Å and 90° for all three angles (Table 16). The 
initial phases were obtained by molecular replacement in phaser (McCoy et al. 2007) 
as part of phenix (Adams et al. 2010) using the search models of another bacterial 
POT DtpD (PDB id: 4Q65) and a nanobody. The model was refined in iterative cycles 
of manual editing of the model in COOT (Emsley and Cowtan 2004) and refinement 
steps in phenix software. The resolution extended to 3.3 Å and the completeness was 
over 99 %. DtpA could be modeled starting from residue 17 to 488 (full length 500 
residues) without any missing loops and N00 from residue 1 to 125 (full length 132 
residues). A single water molecule was included in the model, which is in the ligand-
binding site and is coordinated by R34 and N126 of DtpA. Overall, DtpA is in the 
inward open conformation and the N00 is binding from the periplasmic side of DtpA 
as shown in Figure 30, which is further discussed in section 3.6.2. 
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Figure 30: The structure of DtpA-N00 complex in MES buffer 
The DtpA-N00 structure is illustrated in surface and cartoon representation. The N-
terminal bundle of DtpA is colored green, C-terminal bundle in orange and HAHB 
domain in yellow and the nanobody N00 in pink. Presumed membrane orientation is 
represented with black lines. 
3.5.2. DtpA-N00 complex in glycine buffer 
In parallel to the MES buffer condition, other conditions were further optimized for 
crystallizing DtpA-N00. The second successful crystallization condition was 0.15 M 
CaCl2, 0.1 M glycine, pH 9.0 and 35 % PEG 400. Two types of crystals grew under 
this condition, needle shaped and cubic (Figure 31). Although the cubic crystals were 
larger in volume, they diffracted only up to 15 Å. The needle shaped crystals were 
more promising. The crystals leading to the DtpA-N00 complex in the glycine buffer 
appeared between day 60 and 80 and were flash frozen without an additional 
cryoprotectant due to the presence of high concentrations of PEG 400.  
 
 78 
 
Figure 31: Crystals of DtpA-N00 complex in glycine buffer 
In the glycine condition DtpA-N00 complex gave rise to two different crystal forms, a 
cubic and a needle shape. Only the needle formed crystals yielded diffraction in high 
resolution range. The picture is taken on day 5. 
The diffraction data were collected at P14 beamline operated by EMBL Hamburg at 
PETRA III (DESY, Hamburg, Germany) under cryo conditions. The same method 
was used for data processing as for DtpA-N00 complex structure determination 
(Methods section 2.2.4.2). The space group was the same as for the former structure 
and the unit cell parameters were almost identical. The resolution extended to 3.3 Å 
as for the previous structure. The search model for the molecular replacement step 
was the DtpA-N00 structure in MES buffer (PDB id: 6GS1). The data collection and 
refinement statistics are listed in Table 16. DtpA could be modeled starting from 
residue 17 to 487 (full length 500 residues) without any missing loops and N00 from 
residue 1 to 125 (full length 132 residues). The DtpA-N00 complex in glycine buffer 
is very similar to the structure in MES buffer (Figure 30) with a rmsd of 0.36 Å over 
3985 atoms. The optimization of this condition was crucial due to the difficulties in 
the reproducibility of the MES condition in contrary to the more robust nature of this 
condition for co-crystallization with ligands. 
3.5.3. DtpA-N00 complex with ligands 
Several commercial and self-made optimization crystallization screens based on MES 
and glycine buffer conditions were tested with the DtpA-N00 mixed with one of the 
ligands LeuLeuAla, AlaPheAla, valganciclovir and valacyclovir, in low mM 
concentrations in the crystallization drop. The ligands were selected based on the 
thermal stabilization and binding affinity results (Figure 23 and Table 15). With each 
ligand initial crystals were obtained in the glycine condition. The crystals were in all 
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cases very tiny needles with a high nucleation rate. Only DtpA-N00 with 
valganciclovir crystals improved after several optimization rounds and diffracted to 
high resolution. 
3.5.3.1. DtpA-N00 complex with Valganciclovir  
The crystals of DtpA-N00 in complex with valganciclovir grew in the condition 
0.15 M CaCl2, 0.1 M glycine, pH 9.0, 35 % PEG 400 and 0.02 % Anapoe-C12E10. 
The crystal appeared on day 28 and grew until day 55. They were flash frozen without 
addition of cryoprotectant, as high concentrations of PEG 400 was present in the drop. 
The diffraction data were collected at the P13 beamline operated by EMBL Hamburg 
at PETRA III (DESY, Hamburg, Germany) under cryo conditions. The data 
processing was performed as described for the structure determination of DtpA-N00 
complex in glycine buffer. The resolution extended further to 2.65 Å. The space 
group was the same and the unit cells were almost identical (Table 16). The residues 
17-488 of DtpA (full length 500 residues) and 1-122 of N00 (full length 132 residues) 
were modeled. The DtpA residues 143-144 and 342-343 from the loops within TM4-
TM5 and TM8-TM9 respectively were excluded from the model due to weak electron 
density. They are both loops on the cytoplasmic side of the protein and thereby on the 
opposite side of the N00 binding site. Additionally, one valganciclovir, one 
dodecylmaltoside (DDM) and seven water molecules were built in the electron 
density. The DDM molecule is on the outer surface of the DtpA in the proximity of 
the TM9 and TM12 with the sugar moiety close to the expected water lipid interface 
on the periplasmic side of the protein and the carbon chain aligned along the TM9. 
The water molecules were not in the ligand-binding site but in several other positions 
spread across the inner cavity of DtpA. There was a clear electron density to build 
valganciclovir in the ligand-binding site (Figure 32).  
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Figure 32: Valganciclovir in the ligand-binding site of DtpA 
(a) DtpA in surface representation cut in half with valganciclovir in the ligand-
binding site. (b) Omit map of valganciclovir countered at 3 σ level. (c) The 2Fo-Fc 
map of DtpA refined with both diastereomers countered at 1 σ level. All further 
figures are prepared with diastereomer-1 (left). 
Valganciclovir is a mix of two diastereomers and both were tested for model building 
independently. The backbone of valganciclovir fits the electron density in both cases 
equally well and there is no density corresponding to the -CH2OH group at the chiral 
center for either of the diastereomers (Figure 32). This can be explained by a mixture 
of the two diastereomers in the ligand-binding site of DtpA within the crystal, 
therefore the electron density of the -CH2OH group is weaker. 
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3.6. Analysis of the DtpA-N00 structure 
3.6.1. Overall structure 
The DtpA structure contains 14 transmembrane α-helices (TM), which are organized 
in two bundles: TM 1 to 6, the N-terminal bundle, and TM 7 to 12, the C-terminal 
bundle, forming the transporter core and two additional TMs, HA-HB, placed in 
between (Figure 30). This is in agreement with the previously published bacterial 
POT structures (Newstead et al. 2011; Martinez Molledo et al. 2018; Zhao et al. 
2014) and the predictions based on the sequence analysis of DtpA. The structure is in 
inward open conformation as the formerly published structures from the POT family, 
except PepTSo and PepTSt, which were also captured in partially occluded inward 
open conformation. DtpA shows high structural similarity in the transporter core with 
rmsd values between 1.3 to 2.7 Å along the peptide backbone to previous POT 
structures.  
3.6.2. DtpA-N00 interaction site 
In the DtpA-N00 complex structure, N00 binds to DtpA on the periplasmic side of the 
transporter. Nanobodies have three loops, called the complementarity-determining 
region (CDR) H1, H2 and H3, which are involved in antigen binding. Especially CDR 
H3 is a longer loop, which can bind into crevices. In the case of the DtpA-N00 
interaction, the CDR loops H2 and H3 of the N00 extend into the crevices on the 
periplasmic side of DtpA, spanning across both the N- and C-terminal bundle (Figure 
33).  
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Figure 33: The binding surface of DtpA and N00 
(a) Surface representation of DtpA with N-terminal bundle in green and C-terminal 
bundle in orange, the residues involved in N00 binding are highlighted in blue. The 
N00 is in cartoon representation and the residues on the two loops, CDR H2 and H3, 
involved in DtpA binding are shown in sticks model. (b) LigPlot (Laskowski and 
Swindells 2011) analysis of the DtpA-N00 interaction site.  
The interaction site was investigated with LigPlot (Laskowski and Swindells 2011) 
(Methods section 2.2.4.3). There are hydrophobic interactions between 18 amino 
acids of DtpA and 8 amino acids of N00 (Figure 33). Additionally, there are three 
hydrogen bonds contributing to the interaction. Namely, between the main chain 
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carbonyl group of N00 T54 and the main chain amino group on DtpA T448, between 
the main chain carbonyl group N00 G102 and side chain primary amine group of 
DtpA K50 and between the side chains of N00 Y107 and DtpA E317. The protein-
protein interaction surface area is approximately 4916 Å2 based on the calculations in 
PyMOL. With these interactions N00 stabilizes the inward-open conformation of 
DtpA. 
3.6.3. The role of N00 in the crystallization of DtpA 
In the crystal structure, the asymmetric unit consists of one DtpA and one N00 
molecule and the symmetry is P212121. Within the symmetry mates, one N00 
molecule is in the center of four DtpA molecules forming crystal contacts (Figure 34). 
One of the four binding sites is the DtpA-N00 binding interface with the N00 CDR 
H2 and H3 loops intruding into the cavities on the periplasmic side of DtpA (Figure 
33). The other three interaction sites are crystal contact points, which do not occur in 
solution based on our observations that DtpA is a monomer and binds in a 1:1 ratio 
with N00 using analytical gel filtration analysis. Here, N00 interacts with the loops on 
the cytoplasmic side of DtpA, different than the main DtpA-N00 interaction, which 
occurs on the periplasmic side of DtpA. Noticeably, there are no direct interactions 
between two DtpA molecules but the nanobody plays the central part in crystal 
contact formation. 
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Figure 34: Crystal packing of DtpA-N00 
(a) Four DtpA-N00 complexes are shown in different colors: green, blue, wheat and 
pink. The N00 in pink makes crystal contacts with the loops on the cytoplasmic side 
of the DtpA in other symmetry mates. (b) DtpA is colored in wheat and N00 in pink 
for all symmetry mates.  
There are large volumes of empty space in the crystal packing, as can be seen in 
Figure 34, which is typical for type 2 membrane protein crystals (Figure 35). In this 
crystal type, each membrane protein is covered by the detergent micelle, which is not 
organized in a crystalline order and therefore, not visible in the electron density map. 
The type I crystal form is typical for the LCP crystallization method and leads to 
densely packed crystals with higher signal-to-noise levels and often better resolution; 
unfortunately no crystals were obtained using the LCP method for DtpA with or 
without nanobodies. 
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Figure 35: Type I and type II crystal forms of membrane proteins 
Membrane protein crystallization is often performed by the lipidic cubic phase or 
vapour diffusion methods, which lead to different packing features of the membrane 
protein crystals. In a type I crystal, which is typical for LCP method, the proteins are 
in a continuous membrane layer and can pack densely, whereas in type 2 crystals, 
typical for vapor diffusion method, the detergent micelle prevents the proteins from 
packing densely and there is more space between the proteins. Figure modified from 
(Gouaux 1998). 
3.6.4. Valganciclovir in the ligand-binding site of DtpA 
The DtpA-N00 complex was co-crystallized with valganciclovir. We were able to 
model the valganciclovir with high confidence based on the electron density in the 
ligand-binding site. Valganciclovir is a L-valyl ester of ganciclovir, which is an 
antiviral drug, and has a similar size to tripeptides. Based on the previous 
observations that the N-terminal residue of a di-/tripeptide plays an important role in 
the coordination of the ligand in the binding site and the N-terminal residue of di- and 
tripeptides occupies the same position, it was suggested that the N-terminal valine of 
valganciclovir would also superimpose with the N-terminal residue of di-/tripeptides 
in the binding site (Figure 36).  
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Figure 36: The binding mode of valganciclovir 
(a) The expected binding mode in the literature with the N-terminal valine of 
valacyclovir mimicking the N-terminal residue of a dipeptide, both highlighted in 
pink box, and the guanine ring mimicking an aromatic side chain, both in blue box. 
Figure from (Samsudin et al. 2016). (b) The comparison of PepTSt structure with 
AlaPhe and DtpA structure with valganciclovir. The guanine ring is mimicking the N-
terminal alanine of the dipeptide and the valine of valganciclovir is in a pocket 
created by the TM10 intrahelical loop that is not present in PepTSt. 
Valganciclovir in this expected binding mode did not fit into the electron density 
observed in the ligand-binding site but rather in a 180° rotated binding mode. Here, 
the guanine ring mimics the position of an N-terminal residue, whereas the valine 
moiety intrudes into a pocket, which is smaller in most other POTs with known 
structure as discussed in section 3.6.6. 
The residues coordinating the guanine ring of valganciclovir is equivalent to the 
residues coordinating the N-terminal residue of a di-/tripeptide. Specifically, DtpA 
N160 (TM5), N325 (TM8) and E396 (TM10) make hydrophobic interactions with the 
guanine ring of valganciclovir and the hydroxyl group of DtpA Y156 is likely to form 
a hydrogen bond with an amine group within the guanine ring of the valganciclovir 
(Figure 37). For one of the diastereomers of valganciclovir the hydroxyl group of Y38 
is in the distance for a hydrogen bond with the hydroxyl group in the center of the 
molecule. F289 (TM7) as well as I399 and L402 (TM10), which are part of the 
intrahelical loop discussed in next section, coordinate the valine residue of 
valganciclovir. Overall, valganciclovir guanine ring mimics the interactions with a di-
/tripeptide but the position of the valine is unique due to this intrahelical loop within 
TM10.  
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Figure 37: Valganciclovir in the ligand-binding site of DtpA 
(a) The residues involved in the ligand coordination are shown in sticks model. The 
residues F289 and N325 are excluded for clarity and the residues K130 and Y71 are 
included, because they are typically involved in ligand binding and point towards the 
ligand (Martinez Molledo et al. 2018; Guettou et al. 2014), although they are further 
than 3.5 Å at this conformation. (b) LigPlot (Laskowski and Swindells 2011) analysis 
of the DtpA-valganciclovir binding. 
3.6.5. The difference in TM10-TM11 between DtpA and other POTs 
The major structural difference between DtpA and the previously published POT 
structures is in the TM10 and TM11 region, which is relevant for the coordination of 
the valganciclovir valine moiety. A discontinuity of the TM10 was observed in 
PepTSo2 (Guettou et al. 2013) but was not further investigated. In the DtpA structure, 
this discontinuity is even more pronounced than in PepTSo2 and is involved in the 
coordination of valganciclovir. The periplasmic half of TM10-11 in DtpA and 
PepTSo2 superimposes well with other POT structures. An intrahelical loop in DtpA 
(I399-SGLG-L404) and PepTSo2 at the level of the ligand-binding site causes a shift in 
the cytoplasmic half of TM10 towards TM11 and pushes TM11 further away creating 
a larger pocket in the ligand-binding site (Figure 38). To investigate the length of this 
shift, we have overlaid TM10-11 of DtpA (PDB id: 6GS4) and PepTSt (PDB id: 
5OXN) and measured the distance between the furthest points of TM10 and TM11 
individually. The L404 Cα of TM10 in DtpA and the equivalent L408 Cα atom in 
PepTSt, are 6.1 Å apart (represented with an double-headed arrow (d1) in Figure 38) 
and F424 Cα of TM11 in DtpA and the equivalent F428 Cα in PepTSt are 6.8 Å apart 
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(represented with an double-headed arrow (d2) in Figure 38). The volume of binding 
pocket near TM10-11 was further investigated as described in the next section. 
 
 
Figure 38: The difference in TM10-TM11 between DtpA and other POT 
structures 
(a) Comparison of DtpA (PDB id: 6GS4 in orange) and PepTSt (PDB id: 5OXN in 
grey). The distance between equivalent residues of DtpA and PepTSt at the furthest 
positions are shown with a double-headed arrow. (b) Side-by-side views of DtpA, 
PepTSo2 (PDB id: 4LEP in dark green) and PepTSt. Notably, DtpA and PepTSo2 have 
an intrahelical loop in TM10 and PepTSt does not. (c) left: TM10-11 of other POTs 
than DtpA and PepTSo2 aligned, namely PepTSo (PDB id: 4UVM in magenta), GkPOT 
(PDB id: 4IKV in light green), DtpD (PDB id: 4Q65 in cyan), and YePepT (PDB id: 
4W6V in blue), right: left image is shown in 50% transparency and overlaid with the 
TM10-11 of DtpA and PepTSo2 for comparison. 
3.6.6. Binding pocket volume analysis with focus on TM10-TM11 
The ligand-binding site of POTs is globular with several side pockets, in which 
different side chains of the di-/tripeptides and (pro)drugs can fit. The binding pocket 
near TM10-11 was investigated for DtpA and other POT structures by calculating the 
volume of the ligand binding site using POVME 2.0 (Durrant et al. 2014) as 
described in Methods section 2.2.4.3. 
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For the volume calculation the Cα atom of the valine residue in valganciclovir was 
taken as center and the volume at 4 and 7 Å radii was calculated for all aligned 
structures with default parameters. At both radii, DtpA, PepTSo2 and DtpD cluster 
together with a larger pocket near TM10-TM11 and the other POTs cluster together 
with a smaller pocket (Figure 39). We were surprised to see DtpD in the same 
category as DtpA and PepTSo2, because DtpD does not have an intrahelical loop 
(Figure 38) but TM11 of DtpD is rather similar to DtpA and PepTSo2 and the slight 
side chain differences may lead to a bigger pocket compared to other POTs without 
the TM10 intrahelical loop. 
 
 
Figure 39: The ligand-binding site volume calculation focusing on TM10-TM11 
(a) The calculated volume around the Cα atom of valine in valganciclovir is 
illustrated for DtpA (PDB id: 6GS4), PepTSo2 (PDB id: 4LEP) and PepTSt (PDB id: 
5OXN) in mesh representation at 4 Å radius. Valganciclovir is included in all three 
pictures for comparison. (b) The cavity volume for all published POT structures at 4 
and 7 Å radii around the Cα atom of valine in valganciclovir.  
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3.7. Mutational characterization of DtpA 
To investigate the ligand-binding site of DtpA, five residues were mutated to alanine 
as described in Methods section 2.2.1.6. The residues Y38, Y71, N160 and I399 were 
selected due to their interaction with valganciclovir in the DtpA structure (Figure 37). 
K130 was included because it coordinates di-/tripeptides in previous POT structures 
(Martinez Molledo et al. 2018; Guettou et al. 2014), although it was not in proximity 
of valganciclovir in DtpA structure. The five DtpA mutants were expressed and 
purified as DtpA WT and characterized by thermal stability assay in presence and 
absence of N00. The thermal stability of DtpA mutants is very similar to WT and they 
can all bind to N00 as shown by a strong thermal stabilization effect upon nanobody 
binding (Figure 40).  
 
 
Figure 40: The functional studies with DtpA mutants 
(a) Thermal stability analysis of DtpA WT and mutants with (in red) or without N00 
(in black). (b) AK-AMCA uptake percentage of DtpA WT and mutants. 
Next, the binding affinity of these mutants was tested by the in vitro microscale 
thermophoresis method followed by the in vivo AK-AMCA uptake assay. The 
binding affinity measurements of the mutants to the ligands valganciclovir, 
valacyclovir, LeuLeuAla and AlaLeu were either not possible to determine or reduced 
by several orders of magnitude and no AK-AMCA uptake was observed for the 
mutants (Figure 41 and Figure 42). Surprisingly, the K130A mutation affects the 
binding affinity to valganciclovir and valacyclovir similar to other mutations, 
although in the captured DtpA structure it is not in direct proximity of the ligand. It is 
likely that this residue plays a role in the drug coordination in another conformational 
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state than in the crystal structure. Overall, the functional characterization of the 
mutants is in good agreement with the assignment of the tested residues to the ligand-
binding site in the crystal structure. 
 
Figure 41: The binding affinity curves of DtpA mutants and drugs 
Binding affinity measurements of DtpA mutants with the ligands valganciclovir and 
valacyclovir. 
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Figure 42: The binding affinity curves of DtpA mutants and di-/tripeptides 
Binding affinity measurements of DtpA mutants with the ligands LeuLeuAla and 
AlaLeu. 
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3.8. Homology model of the human PepT1 based on DtpA 
DtpA has been characterized for its similarity to hPepT1 in its ligand selectivity and 
transports drugs taken up by hPepT1 (Weitz et al. 2007; Prabhala et al. 2017). The 
binding affinity of DtpA to valganciclovir and valacyclovir that we have measured 
was also similar to the binding affinity recently measured for valacyclovir to hPepT1 
(Clémençon, Lüscher, and Hediger 2018) with the same method supporting their 
conserved ligand binding profile. In the absence of a eukaryotic POT structure, a 
homology model of the hPepT1 was built by Vasileios Rantos from EMBL Hamburg 
in collaboration. The sequence alignment used in the homology modeling is shown in 
Figure 43. 
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Figure 43: Sequence alignment of DtpA and hPepT1 
(a) The sequence similarity is shown in shades of blue with the darker the color tone 
representing the higher the similarity between DtpA and hPepT1. The transmembrane 
helices are marked with green bars underneath the sequence and the ligand-binding 
site residues with stars above the sequence. The extracellular domain of hPepT1, 
which is not present in DtpA and not included in the homology model, is highlighted 
in yellow. The TM12 of hPepT1 model has lower certainty in the model building and 
therefore shown in an orange box. The black box demonstrates the intrahelical loop 
within TM10 for both DtpA and hPepT1. (b) The conserved ligand-binding site 
residues of DtpA and hPepT1 are shown in a separate table.  
There are two major structural differences between bacterial and human POTs. The 
HAHB domain is present only in the bacterial structure; in eukaryotic POTs there is a 
long linker connecting TM6 and TM7 instead. The extracellular domain is present 
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only in mammalian POTs and the structure thereof was determined recently (Beale et 
al. 2015), which revealed a globular shape consisting of two tightly packed 
immunoglobin-like folds. Nevertheless, there is no insight into how this extracellular 
domain is oriented relative to the transporter core. Therefore, the long linker between 
TM6-TM7 and the extracellular domain of hPepT1 were omitted and only the 
transporter core of hPepT1 was modeled (Figure 44). 
 
 
Figure 44: The ligand-binding site analysis of hPepT1 model with valganciclovir 
(a) Left: Surface and cartoon representation of hPepT1 with the N-terminal bundle 
colored in cyan and the C-terminal bundle in pink. The extracellular domain and the 
long loop connecting TM6 and TM7 are excluded from the model. Middle: The 
surface representation of hPepT1 cut in half to highlight the ligand-binding site in the 
center of the transporter. Valganciclovir is shown in sticks model (yellow). Right: 
Same model with the ligand-binding site residues in stick representation. The dashed 
lines highlight possible hydrogen bonds in less than 3.5 Å distance. The residues 
N329 and L290 are excluded for clarity and the residues K140 and Y64 are included 
due to their role in di-/tripeptide coordination as observed in other POT structures 
(Martinez Molledo et al. 2018), although distant from valganciclovir in this case. (b) 
LigPlot (Laskowski and Swindells 2011) analysis of the ligand-binding site of DtpA 
and hPepT1 side-by-side.  
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The ligand-binding site of DtpA and hPepT1 are highly conserved and the 
ligand-binding site of hPepT1 model resembles the DtpA ligand-binding site (Figure 
37). Valganciclovir fits into the ligand-binding site of hPepT1. The side chains 
coordinating the guanine ring of valganciclovir in hPepT1, namely Y31, Y167, N171, 
N329 and E595, are the equivalent residues of DtpA, Y38, Y156, N160 and E396 
(Figure 44). The hydroxyl group of Y31 is likely to form a hydrogen bond with the 
hydroxyl group at the center of valganciclovir for one of the diastereomers (Figure 8), 
because in the other diastereomer the hydroxyl group is pointing towards another 
direction and is not in proximity. The hydroxyl group of Y167 is likely to form a 
hydrogen bond with the amine group of the guanine ring. We do not see any 
interactions with the middle part of valganciclovir, except the aforementioned 
hydrogen bond. The N-terminal valine is intruding into a pocket and has hydrophobic 
interactions with L290, F598 and T601. Interestingly, these residues are not as 
conserved between hPepT1 and DtpA as the residues coordinating the guanine ring 
but play an equivalent role. 
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4. Discussion and Outlook 
4.1. Homology model of hPepT1 
The human PepT1 is highly expressed in the intestinal cells in humans and plays a 
key role in the nutrient uptake as well as in the absorption of several drugs, such as β-
lactam antibiotics, antiviral drugs and anticancer molecules (Brandsch, Knütter, and 
Bosse-Doenecke 2008). To date, there are no eukaryotic POT structures, but bacterial 
homologues have proven to be good models. There are a few structures of peptide 
transporters with di-/tripeptides, their natural ligands, providing insight into the 
ligand-binding site and the structure-activity relationship. Unfortunately, these 
bacterial POTs are not able to bind or transport drugs. Therefore, in collaboration an 
hPepT1 model was built based on the DtpA structure in complex with valganciclovir. 
To validate the hPepT1 model, I have examined the mutational studies performed 
with hPepT1 in the literature. Three transmembrane helices, namely TM5 (Kulkarni, 
Haworth, and Lee 2003), TM7 (Kulkarni et al. 2003) and TM10 (Xu et al. 2009), 
were systematically studied by mutating each residue to cysteine and measuring the 
uptake of the radioactively labeled [3H]-glycyl-sarcosine (GlySar) in HEK293 cells 
overexpressing these mutants. Most of the residues, which led to less than 25 % 
activity, could be mapped in the model in proximity of the ligand-binding site (Figure 
45). On TM5, these were Y167, N171 and S174, on TM7 F293 and F297 and on 
TM10 E595 and F598. Within the same study, the solvent accessibility was 
investigated and the residues T601-F605 in TM10 were all highly solvent accessible 
(Xu et al. 2009). In a standard continuous α-helix, adjacent residues are not expected 
to be solvent accessible; however in our model this region forms the intrahelical loop 
within TM10 (Figure 45), for which one would expect solvent accessibility, 
supporting the presence of the intrahelical TM10 loop in hPepT1 and our model in 
general. 
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Figure 45: The mutational studies on hPepT1 
(a) hPepT1 model in cartoon representation colored in wheat. The transmembrane 
helices (b) 5, (d) 7 and (c) 10 are colored in blue, red and green respectively. The 
residues, which were suggested to play a role in ligand uptake as well as 
valganciclovir (yellow), are shown in sticks model. The dashed lines represent 
distances up to 5.5 Å.  
hPepT1 is one of the most abundant multidrug transporters in the intestines (Drozdzik 
et al. 2014) and of great pharmacological interest. Few homology models have been 
reported for hPepT1 based on previous bacterial POT structures, which were not 
capable of transporting drugs and did not have the intrahelical loop in TM10 
(Samsudin et al. 2016; Beale et al. 2015), furthermore they were not uploaded on a 
server and accessible to the community. Here, we provide a new homology model 
(accessible in https://www.modelarchive.org upon publication) and expect that it 
would contribute to further studies on ligand selectivity and drug discovery. 
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4.2. The binding mode of valganciclovir and the binding pocket 
near TM10-TM11 
The ligand-binding site of POTs is in the center of the protein, is globular and has 
several side pockets, where different side chains of di- and tripeptides and (pro)drugs 
can fit in. This organic shape makes the ligand-binding site rather difficult to study 
and predict which pockets might be involved in the coordination of the different side 
chains of di- and tripeptides. Furthermore, there are many aromatic residues present in 
the ligand-binding site. These allow versatile interaction modes contributing to the 
promiscuity of the transporter. It is even more challenging to predict the binding 
mode of the peptidomimetic drugs, which mimic the peptide backbone and the side 
chains. However, the selectivity of the ligand-binding site is defined by the space 
available for the ligands within these pockets.  
The binding mode of valacyclovir in hPepT1 was predicted based on the PepTSt 
structure bound to AlaPhe (Samsudin et al. 2016). Here, the valine moiety of 
valacyclovir was positioned as the N-terminal residue of the dipeptide AlaPhe and the 
guanine ring as the aromatic side chain of the C-terminal residue. I have initially 
tested the same binding mode in the electron density within the ligand-binding site of 
the DtpA-valganciclovir crystal structure, but this model was not compatible and thus 
alternative binding modes were tested. The binding mode, where the guanine ring is 
mimicking the N-terminal residue of a di-/tripeptide and the valine moiety extending 
into an uncharacterized pocket near TM10-TM11 was the best model based on the 
electron density map. Indeed, this binding pocket close to TM10-TM11 increases the 
available space within the ligand-binding site and was the major structural difference 
between DtpA and other POTs except for PepTSo2. Interestingly, DtpA and PepTSo2 
have another feature in common, namely both prefer tripeptides to dipeptides, 
whereas other tested POTs have a preference towards dipeptides. Valganciclovir has a 
similar backbone length to a tripeptide and we predict that the newly characterized 
pocket near TM10-TM11 is important not only for the coordination of valganciclovir 
but also for the coordination of tripeptides. 
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4.3. Ligand selectivity of DtpA 
Ligand selectivity of DtpA was characterized by in vitro and in vivo assays, using a 
ligand library consisting of eighteen dipeptides, ten tripeptides and seven drugs. This 
is the most comprehensive study of DtpA so far and the first one to test ligand binding 
and binding affinities in vitro. The in vivo and in vitro studies were in good 
agreement; the former studies were performed in the native environment, the E. coli 
cell membrane, and the latter with the detergent-solubilized protein in solution. The 
results can be summarized in three points:  
First, the tripeptides are preferred over dipeptides. Due to the difficulties of studying 
the ligand selectivity, there is information only for a handful of POTs. PepTSt and 
PepTSo prefer dipeptides over tripeptides in competition assays, and many tripeptides 
did not compete with the used reporter molecule at all (Martinez Molledo et al. 2018; 
Parker et al. 2017). PepTSo2 is the only other POT similar to DtpA, which has a 
preference to tripeptides over dipeptides (Guettou et al. 2014). To our knowledge, 
there are no studies on eukaryotic POTs addressing this point so far.  
The second observation was that the di-/tripeptides with hydrophobic and aromatic 
side chains, independent of their position, are preferred over charged residues. This 
has been indeed observed more than 25 years ago for hPepT1 (Daniel, Morse, and 
Adibi 1992) and recently for other POTs (Guettou et al. 2014; Parker et al. 2017; 
Martinez Molledo et al. 2018) and is likely a general feature of POTs. From an 
evolutionary standpoint, such a preference towards hydrophobic and aromatic 
residues can be explained by the higher metabolic cost of producing these amino acids 
de novo for bacteria, as well as the essential nature of the amino acids in higher 
organisms. Nevertheless, it is possible that there are POTs with a different preference, 
especially in single-cell organisms with multiple POT homologues as suggested for 
DtpC (Jensen et al. 2012). We are still in the early steps of understanding the ligand 
selectivity of POTs and more systematic studies and new methods are required to 
characterize it in depth.  
The third observation in our studies was that the ligands with glycine residues are less 
favored. For example, the thermal stabilization effect of MetSer and HisSer was 
higher than GlySer; similarly, the effect of LeuLeuAla was significantly higher than 
that of LeuGlyGly (Figure 23). No binding affinity could be determined with a ligand 
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containing a glycine residue. This is an important point to make, because several in 
vivo competition assays were performed with glycine containing di-/tripeptides, 
where the effect of the other residue was investigated (Weitz et al. 2007). 
Nevertheless, both GlyGly and GlyGlyGly were shown to be taken up into the cell 
indirectly in a previous study (Weitz et al. 2007). More ligands need to be tested 
containing glycine residues in a systematic approach to characterize the effect of 
glycine. Shortly, the ligand selectivity of DtpA was further characterized and the first 
binding affinity values were determined in low to medium µM range. For ligands with 
small to no effect on the thermal stabilization of DtpA, the binding affinity could not 
be determined. The binding affinity of hPepT1 to valacyclovir was recently 
determined using the same method (MST) as 49 ± 0.3 µM, which is very similar to 
the binding affinity of DtpA to valacyclovir and valganciclovir with 60 ± 13 µM and 
76 ± 16 µM, as shown in this study. These results indicate further similarity between 
DtpA to hPepT1 and support DtpA as a good bacterial model of the human 
transporter. 
4.4. Limitations in studying the ligand selectivity of POTs 
All methods used within this study show binding of the ligand to DtpA, however we 
are interested in the transport of these ligands. It is a common problem in the POT 
field and most studies are based on competition assays with a reporter molecule, AK-
AMCA (Dieck et al. 1999; Groneberg et al. 2001; Weitz et al. 2007; Prabhala et al. 
2017) or a radioactively labeled ligand: [3H]-GlySar (Yeung et al. 1998; Knütter et al. 
2001; Newstead et al. 2011) or [3H]-AlaAla (Solcan et al. 2012; Doki et al. 2013; 
Guettou et al. 2014; Samsudin et al. 2016). The direct transport of the reporter 
molecule is shown for the POT but the competing ligands can be either really 
transported or only binding to the transporter without being moved across the 
membrane. Also the ligands, where no competition is observed, might be nevertheless 
transported but at a much lower rate than the reporter molecule.   
Unfortunately, there are very few methods to study the direct transport of ligands, 
which are difficult to establish, require specific facilities and not compatible with high 
throughput screening of many ligands. The reconstitution of the transporter into 
liposomes with a pH difference inside and out of the liposome to build a proton 
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gradient is the classical approach but it is necessary to use radioactively labeled 
ligands. Often only one radioactively labeled ligand is tested in a direct approach and 
few other ligands are tested in competition. Two major drawbacks from applying this 
method in a systematic way are the limited access to facilities, which allow working 
with radioactivity, and the difficulty to acquire a ligand library consisting of di-
/tripeptides with different chemical features that are radioactively labeled.  
Another approach to measure the direct uptake of the ligands was used for DtpA with 
mass spectroscopy. Here, the E. coli cells were incubated with different drugs and the 
cell content was then analyzed for the occurrence of the drugs by liquid 
chromatography-mass spectrometry  (LC-MS) (Prabhala et al. 2017). The advantage 
of this method is that it is in vivo and without labeling but it is very challenging to 
study di-/tripeptides, which occur naturally in the cell, with this method and requires 
access to a specialized mass spectrometry facility. In summary, although we have 
contributed to the understanding of the ligand selectivity in DtpA with ligand binding 
and competition studies, further work is required to understand the transport profile of 
the ligands. 
4.5. Mutational studies on DtpA 
Five mutations were introduced to DtpA within this study to test the ligand binding 
and transport activity. The DtpA mutants Y38A, Y71A, K130A, N160A and I399A 
lost the AK-AMCA uptake function and had significantly lower binding affinities 
against the selected ligands (Results section 3.7). This shows that the mutations are 
critical not only for ligand binding but also for transport.  
In a previous study, three of these residues were mutated to different amino acids, 
namely Y38F, Y71F and K130R (Jensen et al. 2012), where the AK-AMCA uptake 
was strongly reduced. The same study also investigated Y292F/Y292A, 
S400D/S400N/S400C (Jensen et al. 2012). Both residues are part of the binding 
pocket formed by the TM10 intrahelical loop (Figure 46). In case of Y292F and 
Y292A, the AK-AMCA uptake increased by 1.5- and 4-fold respectively. On the 
DtpA structure, this can be explained by an increase of the binding pocket volume 
upon the mutations. S400 was selected for the mutational study because it is highly 
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conserved between POTs, except for DtpC and DtpD, which have an aspartate at this 
position. All mutations of S400 (S400D, S400N and S400C) inhibited the AK-AMCA 
uptake. Although the side chain of S400 is not pointing towards valganciclovir in the 
DtpA structure, the backbone carboxyl group is in proximity of the ligand. We cannot 
explain the effect of the mutation on the uptake activity in the present inward-open 
conformation of DtpA, but in the occluded or outward-open conformation the side 
chain may constrict the binding pocket size.  
 
 
Figure 46: Position of Y292 and S400 in DtpA structure 
DtpA is colored form blue (N-terminal end) to red (C-terminal end) and the N-
terminal bundle is omitted from the picture for a better view of the ligand-binding 
site. Valganciclovir is shown in yellow sticks model for illustrating the ligand-binding 
site.Y292 and S400, which were mutated (Jensen et al. 2012), are illustrated on the 
DtpA structure as sticks model. 
DtpA was also subjected to a random mutagenesis study, in which 35 point mutations 
led to reduced uptake of AK-AMCA and/or alafosfalin (Malle et al. 2011) (Figure 
47). Most of the mutated residues were likely involved in intramolecular interactions 
between the transmembrane α-helices. There was only one mutated position within 
the ligand-binding site, namely F289, which was mutated to leucine and serine, both 
of which inhibited the AK-AMCA uptake. The most interesting finding of this study 
was the characterization of the periplasmic gate salt bridge. The single mutations of 
E56 and R305 inhibited the AK-AMCA uptake, whereas the double-mutation rescued 
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the uptake activity. In the DtpA structure, E56 and R305 form a hydrogen bond 
(Figure 47). This periplasmic salt bridge is highly conserved among bacterial POTs, 
although in the case of PepTSo, PepTSt and YePepT the positions of glutamate and 
arginine are swapped. 
 
 
Figure 47: Random mutagenesis results mapped on the DtpA structure. 
(a) DtpA in wheat and all mutations (Malle et al. 2011), which led to reduced AK-
AMCA and/or alafosfalin uptake are colored in red. (b) DtpA is colored from blue (N-
terminal end) to red (C-terminal end) and the residues 429-449 (periplasmic loop) are 
omitted from the structure for clarity. The E56 and R305 are shown in sticks model 
and the distance between E56 and R305 is shown as a black dashed line. 
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4.6. The conformational state of DtpA 
To support our understanding of ligand binding and transport, the structure of DtpA 
was determined in both ligand-free and valganciclovir-bound form using a nanobody 
as crystallization chaperone, which stabilized the inward-open conformation of DtpA. 
In fact, almost all POT structures are found in the inward-open conformation. 
Therefore, it is likely that the POTs, at least in the detergent solubilized form, are 
stabilized in this conformation. Nevertheless, it is challenging to investigate the 
conformation of a transporter in solution. 
An interesting outcome of the in vitro assays was that the behavior of DtpA and 
DtpA-N00 was very similar. The binding affinity measurements are sensitive towards 
conformational changes, because the method is based on the differences in size, 
charge and change in hydration shell upon ligand binding; similar changes occur also 
upon conformational change. For the DtpA-N00 complex, we show that DtpA is in an 
inward-open conformation. If DtpA without N00 is yielding the same binding 
affinities towards the same ligands, it is very likely that DtpA is (almost) completely 
in the inward-open conformation in solution as well. It remains an open question, if 
DtpA can change its conformation in detergent-solubilized form. Unfortunately, this 
point was not possible to address within this work and requires further biochemical 
techniques, such as Förster resonance energy transfer (FRET) measurements. 
Noticeably, the ligand binding was studied with the readily formed DtpA-N00 
complex, which is locked in the inward-open conformation, namely the release state. 
For the previous ligand-bound structures of POTs one could assume that the ligand 
did bind to the outward-open conformation in solution and the transition to inward-
open state took place and the crystallization was with the inward open ligand-bound 
state of the POTs. In case of DtpA, the ligand binds directly to DtpA in inward-open 
conformation, so it is possible that also the other POTs were in the inward-open 
conformation in the first place. Why the ligands bind to the transporter in the release 
state and how they are released is still unclear. Further studies on the transport cycle 
in vivo and in vitro will clarify this puzzling observation. 
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4.7. The role of N00 in the crystallization of DtpA 
The first low-resolution structural analysis of a POT was published in 2007 and it was 
a negative stain transmission electron microscopy (TEM) image of the detergent-
solubilized and purified DtpA (Weitz et al. 2007). The first high-resolution structure 
of a POT in 2011 was of a bacterial homologue from Shewanella oneidensis 
(Newstead et al. 2011). Considering the early work on DtpA and its strong similarity 
to human PepT1 in its ligand selectivity, there is a keen interest in the field to 
determine the high-resolution structure of DtpA. In our hands, no initial crystals were 
obtained for DtpA using vapor diffusion technique or the lipidic cubic phase method. 
Only after the addition of nanobodies, initial crystallization of DtpA was observed 
and could be further optimized leading to the structures of DtpA-N00 complex 
(Results section 3.5). The nanobody played a crucial part in the crystallization of 
DtpA by stabilizing DtpA and by forming crystal contact points observed in the 
determined structure as shown in Figure 34. N00 builds interactions with four DtpA 
molecules and there are no direct crystal contacts between two DtpA molecules.  
The binding of N00 was studied in vivo within the natural environment of DtpA by 
two independent methods that confirmed the occurrence of the DtpA-N00 complex in 
the native membrane. First, DtpA and N00 were co-expressed in E. coli cells and the 
uptake assay showed a strongly reduced uptake of AK-AMCA in co-expressing cells 
relative to cells overexpressing DtpA only. The decrease of AK-AMCA uptake 
(Figure 17) can be explained by the majority of DtpA molecules within the inner 
membrane of E. coli being blocked due to the binding of the N00 from the 
periplasmic site of the protein. The second approach was in vivo crosslinking of N00 
to DtpA, which carried a UV-inducible mutation close to the DtpA-N00 binding site. 
Both results confirm the DtpA-N00 complex formation within the cell membrane and 
that the structure of DtpA is a biologically relevant one. 
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4.8. Outlook 
DtpA is one of the first characterized bacterial POTs with striking similarity to the 
human homologue hPept1 (Weitz et al. 2007). Within the scope of this work, the 
structure of DtpA was determined in ligand-free and valganciclovir-bound form and 
the ligand preference was investigated with in vitro and in vivo methods. The binding 
affinity of DtpA was measured for the first time and is in low to medium µM range. A 
preference for tripeptides over dipeptides was observed in DtpA, which is different 
than most other studied POTs and may be explained by an intrahelical loop within 
TM10 and a shift of TM11 that is not observed in the other POT structures. Although 
a few POT structures with di- and tripeptides are available showing a conserved 
binding mode of the peptide backbone and side chains intruding into smaller pockets, 
this is the only structure of a POT with a drug. A homology model of hPepT1 based 
on this structure was built and will be available in https://www.modelarchive.org 
upon publication. Drug design efforts have been so far based on the previous POT 
structures, which cannot transport drugs. We hope that the hPepT1 model based on 
the DtpA-valganciclovir structure will provide a better platform for further efforts in 
drug discovery and development until the structure of hPepT1 or other mammalian 
homologues with similar ligand selectivity are determined. 
POTs have been crystallized in partially occluded or fully inward open 
conformations, including the presented DtpA-N00 complex structures in this work. 
Although this information is valuable, and the residues of the ligand-binding site 
determined from the structure is supported by biochemical analyses, the inward open 
conformation is the release state of the transporter. To improve our understanding of 
the transport process and to aid in drug design studies, it is crucial to obtain an 
outward open conformation. To obtain the outward open conformation, we need a 
better understanding of the conformational changes that take place in vivo and in 
vitro. There is a multitude of open questions related to the conformational changes in 
POTs, such as the trigger for the transition from one conformational state to another, 
the turnover rates of POTs or even if the outward-open state can be stabilized in the 
detergent-solubilized form.  
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With the available structures of DtpA and DtpD (Zhao et al. 2014) from E. coli, other 
aspects of POTs can be studied, such as gene regulation and protein expression 
patterns. E. coli is an ideal bacterial background to study this topic as most methods 
are developed for this organism. E. coli has four POTs, named DtpA to -D that 
genetically cluster into two groups: DtpA and –B in one group and DtpC and –D in 
the other group. The question why unicellular organisms need multiple POTs in 
addition to further peptide transport systems such as the Opp and Dpp system, has not 
been addressed to our knowledge. In E. coli, one could study the ligand selectivity of 
DtpA to -D as well as their expression patterns related to external and internal cues 
supported by structural information giving us a broader picture of peptide transport in 
prokaryotic cells. 
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6. Appendix 
6.1. Crystallographic statistics 
Table 16: Crystallographic statistics for the three DtpA-N00 structures 
 DtpA-N00 in glycine 
buffer PDB id: 6GS7 
DtpA-N00 in MES 
buffer PDB id: 6GS1 
DtpA-N00-Valganciclovir 
PDB id: 6GS4 
Data collection    
Space group P 212121 P 212121 P 212121 
Cell dimensions      
    a, b, c (Å) 55.14 120.53 163.43 55.46 120.72 163.33 54.94 120.19 163.67 
    α, β, γ  (°)  90 90 90  90 90 90 90 90 90 
Resolution (Å) 19.94-3.3 (3.42-3.3)  48.16-3.29 (3.41-3.29) 19.68-2.65 (2.74-2.65) 
Rmerge 21.74 (217.7) 26.73 (186.4) 10.74 (207.7) 
I / σI 7.04 (0.83) 6.37 (1.06) 10.74 (1.06) 
CC1/2 0.992 (0.593) 0.993 (0.498) 0.998 (0.402) 
Completeness (%) 99.02 (99.70) 99.34 (99.47) 98.98 (97.29) 
Redundancy 8.5 (8.8) 6.7 (6.6) 6.4 (6.6) 
    
Refinement    
Resolution (Å) 19.94 3.3 (3.42-3.3) 48.16-3.29 (3.41-3.29) 19.68-2.65 (2.74-2.65) 
No. reflections 16919 (1671) 17219 (1679) 32178 (3122) 
Rwork / Rfree 21.03 / 24.75 25.11 / 26.60 21.57 / 23.96  
No. atoms    
    Protein 4568 4576 4542 
    Ligand/ion   60 
    Water  1 7 
B-factors    
    Protein 108.69 83.22 89.74 
    Ligand/ion   133.49 
    Water  59.18 74.7 
R.m.s. deviations    
    Bond lengths (Å) 0.004 0.004 0.004 
    Bond angles (°) 0.92 0.91 0.64 
*Values in parentheses are for highest-resolution shell. 
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6.2. RUBIC screen 
Table 17: Conditions in RUBIC screen 
Well_No Conc Units Reagent Conc Units Buffer pH 
A1 100 % Ultrapure water 
   A2 
   
0.119 M Citrate 4 
A3 
   
0.119 M Sodium acetate 4.5 
A4 
   
0.119 M Citrate 5 
A5 
   
0.119 M MES 6 
A6 
   
0.119 M Potassium phosphate 6 
A7 
   
0.119 M Citrate 6 
A8 
   
0.119 M Bis-Tris 6.5 
A9 
   
0.119 M MES 6.5 
A10 
   
0.119 M Sodium phosphate 7 
A11 
   
0.119 M Potassium phosphate 7 
A12 
   
0.119 M HEPES 7 
B1 
   
0.119 M MOPS 7 
B2 
   
0.119 M Ammonium acetate 7.3 
B3 
   
0.119 M Tris-HCl 7.5 
B4 
   
0.119 M Sodium phosphate 7.5 
B5 
   
0.119 M Imidazole 7.5 
B6 
   
0.119 M HEPES 8 
B7 
   
0.119 M Tris-HCl 8 
B8 
   
0.119 M Tricine 8 
B9 
   
0.119 M BICINE 8 
B10 
   
0.119 M BICINE 8.5 
B11 
   
0.119 M Tris-HCl 8.5 
B12 
   
0.119 M CHES 9 
C1 0.298 M Sodium chloride 
   
C2 0.298 M 
Sodium 
chloride 0.119 M Citrate 4 
C3 0.298 M 
Sodium 
chloride 0.119 M Sodium acetate 4.5 
C4 0.298 M 
Sodium 
chloride 0.119 M Citrate 5 
C5 0.298 M 
Sodium 
chloride 0.119 M MES 6 
C6 0.298 M 
Sodium 
chloride 0.119 M Potassium phosphate 6 
C7 0.298 M 
Sodium 
chloride 0.119 M Citrate 6 
C8 0.298 M 
Sodium 
chloride 0.119 M Bis-Tris 6.5 
C9 0.298 M 
Sodium 
chloride 0.119 M MES 6.5 
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C10 0.298 M 
Sodium 
chloride 0.119 M Sodium phosphate 7 
C11 0.298 M 
Sodium 
chloride 0.119 M Potassium phosphate 7 
C12 0.298 M 
Sodium 
chloride 0.119 M CHES 7 
D1 0.298 M 
Sodium 
chloride 0.119 M MOPS 7 
D2 0.298 M 
Sodium 
chloride 0.119 M Ammonium acetate 7.3 
D3 0.298 M 
Sodium 
chloride 0.119 M Tris-HCl 7.5 
D4 0.298 M 
Sodium 
chloride 0.119 M Sodium phosphate 7.5 
D5 0.298 M 
Sodium 
chloride 0.119 M Imidazole 8 
D6 0.298 M 
Sodium 
chloride 0.119 M HEPES 8 
D7 0.298 M 
Sodium 
chloride 0.119 M Tris-HCl 8 
D8 0.298 M 
Sodium 
chloride 0.119 M Tricine 8 
D9 0.298 M 
Sodium 
chloride 0.119 M BICINE 8 
D10 0.298 M 
Sodium 
chloride 0.119 M BICINE 8.5 
D11 0.298 M 
Sodium 
chloride 0.119 M Tris-HCl 8.5 
D12 0.298 M 
Sodium 
chloride 0.119 M CHES 9 
E1 
   
0.119 M SPG 4 
E2 
   
0.119 M SPG 4.5 
E3 
   
0.119 M SPG 5 
E4 
   
0.119 M SPG 5.5 
E5 
   
0.119 M SPG 6 
E6 
   
0.119 M SPG 6.5 
E7 
   
0.119 M SPG 7 
E8 
   
0.119 M SPG 7.5 
E9 
   
0.119 M SPG 8 
E10 
   
0.119 M SPG 8.5 
E11 
   
0.119 M SPG 9 
E12 
   
0.119 M SPG 10 
F1 
   
0.024 M HEPES 7.5 
F2 
   
0.06 M HEPES 7.5 
F3 
   
0.149 M HEPES 7.5 
F4 
   
0.298 M HEPES 7.5 
F5 
   
0.024 M Sodium phosphate 7.5 
F6 
   
0.06 M Sodium phosphate 7.5 
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F7 
   
0.149 M Sodium phosphate 7.5 
F8 
   
0.298 M Sodium phosphate 7.5 
F9 
   
0.024 M Tris-HCl 8 
F10 
   
0.06 M Tris-HCl 8 
F11 
   
0.149 M Tris-HCl 8 
F12 
   
0.298 M Tris-HCl 8 
G1 0.06 M 
Sodium 
chloride 0.06 M HEPES 7.5 
G2 0.149 M 
Sodium 
chloride 0.06 M HEPES 7.5 
G3 0.298 M 
Sodium 
chloride 0.06 M HEPES 7.5 
G4 0.595 M 
Sodium 
chloride 0.06 M HEPES 7.5 
G5 0.893 M 
Sodium 
chloride 0.06 M HEPES 7.5 
G6 1.19 M 
Sodium 
chloride 0.06 M HEPES 7.5 
G7 0.06 M 
Sodium 
chloride 0.06 M Tris-HCl 8 
G8 0.149 M 
Sodium 
chloride 0.06 M Tris-HCl 8 
G9 0.298 M 
Sodium 
chloride 0.06 M Tris-HCl 8 
G10 0.595 M 
Sodium 
chloride 0.06 M Tris-HCl 8 
G11 0.893 M 
Sodium 
chloride 0.06 M Tris-HCl 8 
G12 1.19 M 
Sodium 
chloride 0.06 M Tris-HCl 8 
H1 
   
0.06 M MES/Bis-Tris 6 
H2 
   
0.06 M MES/Imidazole 6.5 
H3 
   
0.06 M Bis-Tris/PIPES 6.5 
H4 
   
0.06 M 
MOPS/Bis-Tris 
propane 7 
H5 
   
0.06 M Phosphate/Citrate 7.5 
H6 
   
0.06 M 
MOPS/Sodium 
HEPES 7.5 
H7 
   
0.06 M BICINE/Tris 8.5 
H8 0.119 M 
Sodium 
chloride 0.06 M Imidazole 7.5 
H9 0.119 M 
Sodium 
chloride 0.149 M Imidazole 7.5 
H10 0.119 M 
Sodium 
chloride 0.298 M Imidazole 7.5 
H11 0.119 M 
Sodium 
chloride 0.417 M Imidazole 7.5 
H12 0.119 M 
Sodium 
chloride 0.595 M Imidazole 7.5 
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